Amer Zeidan, MBBS
Biography
Research & Publications
Patient Care
News
Locations
Appointments
Biography
Amer Zeidan, MBBS, MHS @Dr_AmerZeidan is an Associate Professor of Medicine (Hematology) at Yale University. He is also the medical director of Hematology Early Therapeutics Research, the leader of the Myeloid malignancies Clinical Research Team (CRT), and the director of Continuing Medical Education (CME) at the Hematology division at Yale Cancer Center. Dr. Zeidan completed a hematology/oncology fellowship and a clinical research fellowship in myelodysplastic syndromes (MDS) at Johns Hopkins University where he also earned a Master of Health Science (MHS) degree in Clinical Investigation. Dr. Zeidan specializes in the management of myeloid malignancies especially MDS and acute myeloid leukemia (AML).
The focus of Dr. Zeidan’s clinical/translational research is the development of novel therapies for myeloid malignancies, with a special focus on targeted therapies and immunotherapy-based approaches. Dr. Zeidan is also active in health outcomes and comparative effectiveness research for blood cancers and their therapies. Dr. Zeidan has and continues to serve as the principal investigator of many investigator-initiated, cooperative group and industry sponsored clinical trials for myeloid malignancies.
Dr. Zeidan also chairs or serves on the steering committees of several large clinical trials of myeloid malignancies. He has served as the vice chair of the Yale Cancer Center Data and Safety Monitoring Committee (YCC DSMC) and currently serves in the independent data and safety monitoring committees of multiple clinical trials. Dr. Zeidan is a member of the MyeloMATCH Precision medicine initiative of the National Cancer Institute (NCI) for both MDS and AML and is very active within the Cancer Therapy Evaluation Program (CTEP) and Early Therapy Clinical Trial Network (ETCTN) in working on early phase clinical trials of novel therapies for myeloid malignancies.
Dr. Zeidan has presented his research in many meetings and has been an invited speaker nationally and internationally. He regularly reviews abstracts for the American Society of Hematology (ASH) annual meetings and chairs meeting sessions. He has been presented on MDS in the ASH Annual highlights meetings in USA and Asia-Pacific as well as the ASH Meeting on Hematologic Malignancies. He is also active within the International Working Group (IWG) of MDS and has previously served on the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines panel for MDS.
Dr. Zeidan has received several prestigious awards including the Leukemia and Lymphoma Society Scholar in Clinical Research award, the National Cancer Institute Cancer Clinical Investigator Team Leadership award, the AAMDSIF/Evan’s Foundation-MDS Clinical Research Consortium Fellowship award, the Tito Bastianello Young Investigator Award, the ASCO Young Investigator Award, and multiple other achievement awards. Dr. Zeidan also serves on the editorial board and is a reviewer of several important hematology and oncology journals. He is an author on more than 260 peer-reviewed publications and book chapters.
Education & Training
- MHSJohns Hopkins University (2014)
- FellowshipJohns Hopkins Hospital (2013)
- InternshipRochester General Hospital (2010)
- MBBSUniversity of Jordan (2001)
Activities
- MDS: Meet the Expert VIMarseille, Provence-Alpes-Côte d'Azur, France 2023The 17th International Congress of Myelodysplastic Syndromes: Issues in the Classification of MDS and in Response Criteria : The Devil is in the Details
- Workshop Chair: New Classifications of MDS/CMML, and Response CriteriaMarseille, Provence-Alpes-Côte d'Azur, France 2023The 17th International Congress of Myelodysplastic Syndromes
- MDS: Meet the Expert VIMarseille, Provence-Alpes-Côte d'Azur, France 2023The 17th International Congress on Myelodysplastic Syndromes
- PATIENTS’ PERSPECTIVES ON ORAL DECITABINE AND CEDAZURIDINE FOR THE TREATMENT OF MYELODYSPLASTIC SYNDROMESMarseille, Provence-Alpes-Côte d'Azur, France 202317th International Congress on Myelodysplastic Syndromes
- Panel Discussion: Workshop 02: New Classifications of MDS/CMML, and Response CriteriaMarseille, Provence-Alpes-Côte d'Azur, France 202317th International Congress on Myelodysplastic Syndromes
- Evolution of response criteria in higher risk MDS: The case for changeMarseille, Provence-Alpes-Côte d'Azur, France 202317th International Congress on Myelodysplastic Syndromes
- AS03-Health Economics & Outcome Research/AS03a-Cost of care: ARE WE READY TO PERFORM NGS FOR ALL MDS PATIENTS?Marseille, Provence-Alpes-Côte d'Azur, France 2023The 17th International Congress of Myelodysplastic Syndromes
- AS08-Treatment/AS08f-Clinical trials – Phase II-III: EFFICACY AND SAFETY OF ORAL DECITABINE/CEDAZURIDINE (ASTX727) IN THE CMML SUBPOPULATION FROM PHASE 2 AND ASCERTAIN PHASE 3 STUDIESMarseille, Provence-Alpes-Côte d'Azur, France 2023The 17th International Congress of Myelodysplastic Syndromes
- AS08-Treatment/AS08a-Current treatment options – Higher risk MDS: DEMOGRAPHIC AND CLINICAL CHARACTERISTICS AMONG PATIENTS WITH MYELODYSPLASTIC SYNDROMES RECEIVING ORAL DECITABINE AND CEDAZURIDINE OR INTRAVENOUS/SUBCUTANEOUS HYPOMETHYLATING AGENTS IN A REAL-WORLD SETTINGMarseille, Provence-Alpes-Côte d'Azur, France 2023The 17th International Congress of Myelodysplastic Syndromes
- AS08-Treatment/AS08f-Clinical trials – Phase II-III: RANDOMIZED PHASE 2 STUDY TO ASSESS SAFETY AND EFFICACY OF LOW-DOSE (LD) ORAL DECITABINE/CEDAZURIDINE (ASTX727) IN LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS) PATIENTS: INTERIM SAFETY ANALYSISMarseille, Provence-Alpes-Côte d'Azur, France 2023The 17th International Congress of Myelodysplastic Syndromes
- AS08-Treatment/AS08f-Clinical trials – Phase II-III: PHASE 2 STUDY OF ORAL DECITABINE AND CEDAZURIDINE IN COMBINATION WITH MAGROLIMAB FOR PREVIOUSLY UNTREATED SUBJECTS WITH INTERMEDIATE TO VERY HIGH-RISK MYELODYSPLASTIC SYNDROMES (MDS)Marseille, Provence-Alpes-Côte d'Azur, France 2023The 17th International Congress of Myelodysplastic Syndromes
- When to Use Which Molecular Prognostic Scoring System in the Management of Patients with MDSCarlsbad, CA, United States 2023Acute Leukemia Forum (ALF)
- When to Use Which Molecular Prognostic Scoring System in the Management of Patients with MDSCarlsbad, CA, United States 2023Acute Leukemia Forum (ALF)
- Evolving Clinical Perspectives for High-Risk and Relapsed/Refractory Acute Myeloid Leukemia ManagementVirtual 2023University of Texas San Antonio
- Evolving Clinical Perspectives for High-Risk and Relapsed/Refractory Acute Myeloid Leukemia ManagementMiami, FL, United States 2023Miami Baptist Cancer Institute
- How Do I Manage Myelodysplastic Syndromes/Neoplasms in 2023 (with selected ASH 2022 updates)?Omaha, NE, United States 20232023 Hematology Highlights: A Post ASH Review
- Keynote Talk – How Do I Manage Myelodysplastic Syndromes/Neoplasms in 2023 (with selected ASH 2022 updates)?Virtual 2023University of Kentucky Annual Review of Hematology and Immunotherapy
- Higher Risk Myelodysplastic Syndromes/Neoplasms-What is New?Miami, FL, United States 2023The 27th Annual International Congress on Hematologic Malignancies: Focus on Leukemias, Lymphomas, and Myeloma
- Higher Risk Myelodysplastic Syndromes/Neoplasms – What is New?Miami, FL, United States 2023The 27th Annual International Congress on Hematologic Malignancies: Focus on Leukemias, Lymphomas, and Myeloma
- Keynote Talk – How do I manage Myelodysplastic Syndromes/Neoplasms in 2023 (with selected ASH 2022 updates)?Virtual 2023Annual Review of Hematology and Immunotherapy. University of Kentucky
- Evolving Clinical Perspectives for High-Risk and Relapsed/Refractory Acute Myeloid Leukemia ManagementSan Antonio, TX, United States 2023Plexus MDS at University of Texas San Antonio
- Evolving Clinical Perspectives for High-Risk and Relapsed/Refractory Acute Myeloid Leukemia ManagementMiami, FL, United States 2023Plexus MDS at Miami Baptist Cancer Institute
- How do I manage Myelodysplastic Syndromes/Neoplasms in 2023 (with selected ASH 2022 updates)?Omaha, NE, United States 20232023 Hematology Highlights: A Post ASH Review
- Updates from ASH 2021 meeting in MDS and AML, American Society of Hematology 2021 ReviewVirtual 2023Atlantic Health system
- Myelodysplastic Syndromes (Neoplasms)Seattle, WA, United States 20232023 Official Highlights of ASH in North America
- Myelodysplastic Syndromes (Neoplasms)San Francisco, CA, United States 20232023 Official Highlights of ASH in North America
- Myelodysplastic Syndromes (Neoplasms)New York, NY, United States 20232023 Official Highlights of ASH in North America
- Immune checkpoint inhibition for AML and MDS: Is there a way forward?Houston, TX, United States 2023University of Texas MD Anderson Cancer Center
- Evolving Clinical Perspectives for High-Risk and Relapsed/Refractory Acute Myeloid Leukemia ManagementVirtual 2023Northside Hospital
- Immune checkpoint inhibition for AML and MDS: Is there a way forward?Houston, TX, United States 2023University of Texas MD Anderson Cancer Center
- Myelodysplastic Syndromes (Neoplasms)Seattle, WA, United States 20232023 Official Highlights in North America
- Myelodysplastic Syndromes (Neoplasms)San Francisco, CA, United States 20232023 Official Highlights in North America
- Myelodysplastic Syndromes (Neoplasms)New York, NY, United States 20232023 Official Highlights in North America
- Evolving Clinical Perspectives for High-Risk and Relapsed/Refractory Acute Myeloid Leukemia ManagementVirtual 2023Plexus MDS at Northside Hospital
- Burden of Illness in Patients with Higher-Risk Myelodysplastic Syndromes By Baseline Transfusion StatusNew Orleans, LA, United States 2022American Society of Hematology Annual Meeting
- Understanding What Matters to Myelodysplastic Syndrome Patients – a Study of Preferences for Treatments with Hypomethylating AgentsNew Orleans, LA, United States 2022American Society of Hematology Annual Meeting
- Phase 2 Study of Oral Decitabine/Cedazuridine in Combination with Magrolimab for Previously Untreated Subjects with Intermediate to Very High-Risk Myelodysplastic Syndromes (MDS)New Orleans, LA, United States 2022American Society of Hematology Annual Meeting
- Primary Results of Stimulus-MDS1: A Randomized, Double-Blind, Placebo-Controlled Phase II Study of TIM-3 Inhibition with Sabatolimab Added to Hypomethylating Agents (HMAs) in Adult Patients with Higher-Risk Myelodysplastic Syndromes (MDS)New Orleans, LA, United States 2022American Society of Hematology Annual Meeting
- Streamline – Retrospective Cohort Study of FLT3-mutated Acute Myeloid Leukemia (AML): Real-World Treatment Patterns and Clinical Outcomes after First Relapse or Refractory (R/R) DiagnosisNew Orleans, LA, United States 2022American Society of Hematology Annual Meeting
- Safety of Deferiprone in Patients with Myelodysplastic Syndromes: Results from the Deferiprone US Safety Registry and a Compassionate Use ProgramNew Orleans, LA, United States 2022American Society of Hematology Annual Meeting
- Real-World Treatment Patterns and Transfusion Burden Among Newly Diagnosed Older Adults with Acute Myeloid LeukemiaNew Orleans, LA, United States 2022American Society of Hematology Annual Meeting
- Treatment Patterns and Characteristics Among Patients with Myelodysplastic Syndromes Initiating Oral Decitabine and Cedazuridine or Intravenous/Subcutaneous Hypomethylating Agents in a Real-World SettingNew Orleans, LA, United States 2022American Society of Hematology Annual Meeting
- Cost-Effectiveness of Azacitidine and Ivosidenib in Newly Diagnosed Older, Intensive Chemotherapy-Ineligible Patients with IDH1-Mutant Acute Myeloid LeukemiaNew Orleans, LA, United States 2022American Society of Hematology Annual Meeting
- An expert discussion on myelodysplastic syndromes: current and future personalized management approachesNew Orleans, LA, United States 2022Friday Satellite Symposia at the American Society of Hematology Annual Meeting
- The Characteristics and Prognosis of Patients with Clonal Cytopenias of Undetermined Significance, Including Cancer and Therapy-Related Clonal CytopeniasNew Orleans, LA, United States 2022American Society of Hematology Annual Meeting
- Randomized Phase II Study to Assess the Role of Nivolumab As Single Agent to Eliminate Minimal Residual Disease and Maintain Remission in Acute Myelogenous Leukemia (AML) Patients after Chemotherapy (NCI9706 protocol; REMAIN Trial)New Orleans, LA, United States 2022American Society of Hematology Annual Meeting
- Disease Characteristics and International Prognostic Scoring Systems (IPSS, IPSS-R, IPSS-M) in Adult Patients with Higher-Risk Myelodysplastic Syndromes (MDS) Participating in Two Randomized, Double-Blind, Placebo-Controlled Studies with Intravenous Sabatolimab Added to Hypomethylating Agents (HMA) (STIMULUS-MDS1 and MDS2).New Orleans, LA, United States 2022American Society of Hematology Annual Meeting
- Imetelstat Achieved Prolonged, Continuous Transfusion Independence (TI) in Patients with Heavily Transfused Non-Del(5q) Lower-Risk Myelodysplastic Syndrome (LR-MDS) Relapsed/Refractory (R/R) to Erythropoiesis Stimulating Agents (ESAs) within the IMerge Phase 2 StudyNew Orleans, LA, United States 2022American Society of Hematology Annual Meeting
- Multiple Episodes of Transfusion Independence with Luspatercept Treatment and the Impact of Dose Escalation in Patients with Lower-Risk Myelodysplastic Syndromes from the MEDALIST StudyNew Orleans, LA, United States 2022American Society of Hematology Annual Meeting
- Molecular, Epigenetic, and Immune Landscape of TP53-mutated (TP53-M) Acute Myeloid Leukemia (AML) and Higher Risk Myelodysplastic Syndromes (HR-MDS)New Orleans, LA, United States 2022American Society of Hematology Annual Meeting
- Prolonged Survival in Bi-Allelic TP53-Mutated (TP53mut) MDS Subjects Treated with Oral Decitabine/Cedazuridine in the Ascertain Trial (ASTX727-02)New Orleans, LA, United States 2022American Society of Hematology Annual Meeting
- Characterization of Patients with Lower-Risk Myelodysplastic Syndromes Experiencing Long-Term Responses with Luspatercept in the MEDALIST StudyNew Orleans, LA, United States 2022American Society of Hematology Annual Meeting
- International Working Group (IWG) Response Criteria and Association with Overall Survival in Patients with Myelodysplastic Syndromes Treated with Hypomethylating Agents – a Systematic Review and Meta-AnalysisNew Orleans, LA, United States 2022American Society of Hematology Annual Meeting
- Second Malignancies Among Older Patients with Classical Myeloproliferative Neoplasms Treated with RuxolitinibNew Orleans, LA, United States 2022American Society of Hematology Annual Meeting
- Impact of Allelic State on Overall Survival in TP53-mutant Acute Myeloid Leukemia (AML) and Higher Risk Myelodysplastic Syndromes (HR-MDS)New Orleans, LA, United States 2022American Society of Hematology Annual Meeting
- How Many Stratification Factors Are Reasonable and Can There be Too Many? Evaluation of Analysis Strategies in the Context of a Randomized Phase 2 Trial in Acute Myeloid Leukemia within the Myelomatch PlatformNew Orleans, LA, United States 2022American Society of Hematology Annual Meeting
- A Multi-Center Phase Ib Trial of the Histone Deactylase Inhibitor (HDACi) Entinostat in Combination with Anti-PD1 Antibody Pembrolizumab in Patients with Refractory/Relapsed Myelodysplastic Syndromes (RR-MDS) or Oligoblastic Acute Myeloid Leukemia (RR-AML) after Hypomethylating Agent (HMA) FailureNew Orleans, LA, United States 2022American Society of Hematology Annual Meeting
- Umbrella Trial in Myeloid Malignancies: The Myelomatch National Clinical Trials Network Precision Medicine InitiativeNew Orleans, LA, United States 2022American Society of Hematology Annual Meeting
- Real-World Practice Patterns and Outcomes Following Bruton Tyrosine Kinase Inhibitors (BTKi) in Older Patients with Mantle Cell Lymphoma (MCL): A Population-Based AnalysisNew Orleans, LA, United States 2022American Society of Hematology Annual Meeting
- Primary Results of Stimulus-MDS1: A Randomized, Double-Blind, Placebo-Controlled Phase II Study of TIM-3 Inhibition with Sabatolimab Added to Hypomethylating Agents (HMAs) in Adult Patients with Higher-Risk Myelodysplastic Syndromes (MDS)New Orleans, LA, United States 2022American Society of Hematology Annual Meeting
- Safety of Deferiprone in Patients with Myelodysplastic Syndromes: Results from the Deferiprone US Safety Registry and a Compassionate Use ProgramNew Orleans, LA, United States 2022American Society of Hematology Annual Meeting
- An Expert Discussion on Myelodysplastic Syndromes: Current and Future Personalized Management ApproachesNew Orleans, LA, United States 2022Friday Satellite Symposia, American Society of Hematology Annual Meeting
- A Review of Current and Emerging Treatment Options for Myelodysplastic Syndromes.Atlanta, GA, United States 2022Friday Satellite Symposia - American Society of Hematology 63rd Meeting
- Venetoclax Plus Azacitidine (VEN-AZA) Vs. Intensive Chemotherapy (IC) As Induction for Patients with Acute Myeloid Leukemia (AML): Retrospective Analysis of an Electronic Medical Records (EMR) Database in the United StatesAtlanta, GA, United States 2022American Society of Hematology 63rd Meeting
- The evolving landscape of prognostication and management of myelodysplastic syndromesPittsburgh, PA, United States 2022University of Pittsburgh Grand Rounds
- Evolving Clinical Perspectives for High-Risk and Relapsed/Refractory Acute Myeloid Leukemia ManagementVirtual 2022Nashville VA Hospital
- Evolving Clinical Perspectives for High-Risk and Relapsed/Refractory Acute Myeloid Leukemia ManagementVirtual 2022Plexus MDS at Nashville VA
- The evolving landscape of prognostication and management of myelodysplastic syndromesPittsburgh, PA, United States 2022University of Pittsburgh Grand Rounds
- MDS 2022: What’s New? How does risk stratification determine treatment?New York, NY, United States 2022Lymphoma, Leukemia, & Myeloma Congress
- Emerging Therapies in the treatment of patients with HMA FailureMadrid, MD, Spain 202264th National Congress of the Spanish Hematology and Hemotherapy Society, and 38th National Congress of the Spanish Society of Thrombosis and Hemostasis
- Venetoclaz and Azacitidine for R/R MDSNice, Provence-Alpes-Côte d'Azur, France 2022The 4th International Workshop on Acute Leukemias
- New approved and emerging therapeutic approaches in myelodysplastic syndromesSão Paulo, SP, Brazil 2022HEMO 2022: Brazilian Congress of Hematology, Hemotherapy, and cell therapy
- Evolving Clinical Perspectives for High-Risk and Relapsed/Refractory Acute Myeloid Leukemia ManagementVirtual 2022John H. Stroger Hospital of Cook County
- Evolving Clinical Perspectives for High-Risk and Relapsed/Refractory Acute Myeloid Leukemia ManagementVirtual 2022Miami Valley Hospital
- Evolving Clinical Perspectives for High-Risk and Relapsed/Refractory Acute Myeloid Leukemia ManagementVirtual 2022St. Michael’s Medical Center
- How Do Molecular Aberrations Guide Therapy in Myelodysplastic Syndromes?Guadalajara, Jal., Mexico 2022AMEH-ASH Joint Symposia
- Immune Checkpoint Inhibition for AML and MDS: Is there a way forward?Barcelona, CT, Spain 2022Josep Carreras Leukaemia Research Institute
- MDS 2022: What’s New? How does risk stratification determine treatment?New York, NY, United States 2022Lymphoma, Leukemia, & Myeloma Congress
- Venetoclax and Azacitidine for R/R MDSNice, Provence-Alpes-Côte d'Azur, France 20224th International Workshop on Acute Leukemias
- Immune checkpoint inhibition for AML and MDS: Is there a way forward?Barcelona, CT, Spain 2022Josep Carreras Leukaemia Research Institute
- Emerging Therapies in the treatment of patients with HMA FailureBarcelona, CT, Spain 202264th National Congress of the Spanish Hematology and Hemotherapy Society, and 38th National Congress of the Spanish Society of Thrombosis and Hemostasis
- New approved and emerging therapeutic approaches in myelodysplastic syndromesSão Paulo, SP, Brazil 2022HEMO 2022: Brazilian Congress of Hematology, Hemotherapy, and cell therapy
- How Do Molecular Aberrations Guide Therapy in Myelodysplastic SyndromesGuadalajara, Jal., Mexico 2022AMEH-ASH Joint Symposia
- Evolving Clinical Perspectives for High-Risk and Relapsed/Refractory Acute Myeloid Leukemia ManagementVirtual 2022Plexus MDS at John H. Stroger Jr. Hospital of Cook County
- Evolving Clinical Perspectives for High-Risk and Relapsed/Refractory Acute Myeloid Leukemia ManagementVirtual 2022Plexus MDS at Miami Valley Hospital
- Evolving Clinical Perspectives for High-Risk and Relapsed/Refractory Acute Myeloid Leukemia ManagementNewark, NJ, United States 2022Plexus MDS at St. Michael’s Medical Center
- How I treat MDS – non-transplant managementVirtual 20225th Annual Meeting of the International Academy for Clinical Hematology (IACH)
- The Evolving Treatment Landscape for Higher-Risk Myelodysplastic SyndromeVirtual 2022Plexus MDS Patient Program with LDF
- Venetoclax and Azacitidine for R/R MDSNice, Provence-Alpes-Côte d'Azur, France 2022The 4th International Workshop on Acute Leukemias
- Updates in immune checkpoint inhibitor use in AMLNice, Provence-Alpes-Côte d'Azur, France 2022International Workshop on Acute Leukemias (iwAL)
- A Phase 1 Trial of Ipilimumab in Patients with Myelodysplastic Syndromes after Hypomethylating Agents FailureAlexandria, VA, United States 20222017 American Society of Clinical Oncology (ASCO)/Conquer Cancer Foundation (CCF) Scientific Career Development Retreat/Workshop
- Updates in Immune checkpoint inhibitor use in AMLNice, Provence-Alpes-Côte d'Azur, France 2022International Workshop on Acute Leukemias (iwAL)
- How I Treat MDS – non-transplant managementVirtual 20225th Annual Meeting of the International Academy for Clinical Hematology (IACH)
- The Evolving Treatment Landscape for Higher-Risk Myelodysplastic SyndromeVirtual 2022Plexus MDS Patient Program with LRF
- How I treat Myelodysplastic Syndromes/Neoplasms in 2022Hartford, CT, United States 2022New England Hematological Malignancies Symposium 2022
- The Evolving Treatment Landscape for Higher-Risk Myelodysplastic SyndromeSan Antonio, TX, United States 2022University of Texas Southwestern
- The Evolving Treatment Landscape for Higher-Risk Myelodysplastic SyndromeMiami, FL, United States 2022Plexus MDS at Miami Cancer Institute
- The Evolving Treatment Landscape for Higher-Risk Myelodysplastic Syndrome.San Antonio, TX, United States 2022Plexus MDS at UTSW
- Updates on AML/MDSNew York, NY, United States 2022Keynote Lecture at the 6th Annual International Congress on Oncology Pathology
- Academic perspective: What should approval endpoints be?Miami, FL, United States 20221st iwMDS Meeting
- PD1/PDL-1/CTLA-4, and TIM-3 targeting in MDSMiami, FL, United States 20221st iwMDS Meeting
- AML/MDS updateVirtual 2022AML/MDS update PER talk
- FLT3-Mutated Acute Myeloid Leukemia (AML): Can We Move Front-Line Therapy Forward?Vienna, Vienna, Austria 2022MedScape Satellite symposium in EHA
- Lower-risk MDS Treatment: What have we learnt from Clinical Trials?Vienna, Vienna, Austria 2022BMS Satellite Symposium at EHA: AML and Lower-risk MDS: from Trials to Practice
- Latest Guidance on the Treatment of Higher-Risk MDS and Managing Relapsed/Refractory MDSChicago, IL, United States 2022CCO ASCO MDS Symposium: Therapeutic Advances in Myelodysplastic Syndromes: From Investigation to Clinical Practice
- PATIENT AND PHYSICIAN CHARACTERISTICS ASSOCIATED WITH HYPOMETHYLATING AGENT USE IN HIGHER-RISK MYELODYSPLASTIC SYNDROMESVienna, Vienna, Austria 2022European Hematology Association 2022 Annual Meeting
- SABATOLIMAB (MBG453) COMBINATION TREATMENT REGIMENS FOR PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES: THE MYELODYSPLASTIC SYNDROMES STUDIES IN THE STIMULUS IMMUNO-MYELOID CLINICAL TRIAL PROGRAMVienna, Vienna, Austria 2022European Hematology Association 2022 Annual Meeting
- CLINICAL OUTCOMES IN PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES RECEIVING HYPOMETHYLATING AGENTS: A LARGE POPULATION-BASED ANALYSISVienna, Vienna, Austria 2022European Hematology Association 2022 Annual Meeting
- FIRST RESULTS OF A PHASE II STUDY (STIMULUS-AML1) INVESTIGATING SABATOLIMAB + AZACITIDINE + VENETOCLAX IN PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIAVienna, Vienna, Austria 2022European Hematology Association 2022 Annual Meeting
- REAL-WORLD EFFICACY OUTCOMES OF VENETOCLAX PLUS AZACITIDINE VS INTENSIVE CHEMOTHERAPY FOR INDUCTION THERAPY IN ADULT PATIENTS WITH ACUTE MYELOID LEUKEMIAVienna, Vienna, Austria 2022European Hematology Association 2022 Annual Meeting
- Body mass index and venetoclax-hypomethylating agent induction therapy for acute myeloid leukemiaChicago, IL, United States 2022American Society of Clinical Oncology Annual Meeting
- Treatment patterns and real-world effectiveness of rituximab maintenance in older patients with mantle cell lymphoma: A population-based analysesChicago, IL, United States 2022American Society of Clinical Oncology Annual Meeting
- Long-term utilization and benefit of luspatercept in patients (pts) with lower-risk myelodysplastic syndromes (LR-MDS) from the MEDALIST trialChicago, IL, United States 2022American Society of Clinical Oncology Annual Meeting
- Health-related quality of life (HRQoL) with enasidenib versus conventional care regimens in older patients with late-stage mutant-IDH2 relapsed or refractory acute myeloid leukemia (R/R AML)Chicago, IL, United States 2022American Society of Clinical Oncology Annual Meeting
- Keynote Lecture - Updates on AML/MDSNew York, NY, United States 20226th Annual International Congress on Oncology Pathology.
- Academic perspective: What should approval endpoints be?Miami, FL, United States 20221st iwMDS Meeting
- PD1/PDL-1/CTLA-4, and TIM-3 targeting in MDSMiami, FL, United States 20221st iwMDS Meeting
- Keynote talk: An update on AML/MDSVirtual 2022PER's 6th Annual International Congress on Oncology & Pathology
- FLT3 Inhibitors in Practice – Which Strategy?Vienna, Vienna, Austria 2022MedScape Satellite symposium in EHA. FLT3-Mutated Acute Myeloid Leukemia (AML): Can We Move Front-Line Therapy Forward?
- Lower-risk MDS Treatment: What have we learnt from Clinical Trials?Vienna, Vienna, Austria 2022BMS Satellite Symposium at EHA: AML and Lower-risk MDS: from Trials to Practice
- Latest Guidance on the Treatment of Higher-Risk MDS and Managing Relapsed/Refractory MDSChicago, IL, United States 2022CCO ASCO MDS Symposium: Therapeutic Advances in Myelodysplastic Syndromes: From Investigation to Clinical Practice
- Bringing AML approaches to high-risk SMD. Is it working?São Paulo, SP, Brazil 2022Invited talk in Sintoma Hematologic Malignancies (SOHO Brazil) 2022 annual meeting: Myelodysplastic Syndromes
- How is the great barrier of highly resistant myeloid neoplasms being overcome? Learn how it is being doneSão Paulo, SP, Brazil 2022Invited talk in Sintoma Hematologic Malignancies (SOHO Brazil) 2022 annual meeting: Myelodysplastic Syndromes
- When low-risk MDS behaves badlySão Paulo, SP, Brazil 2022Sintoma Hematologic Malignancies (SOHO Brazil) 2022 annual meeting: Myelodysplastic Syndromes
- Q&A SessionSão Paulo, SP, Brazil 2022Sintoma Hematologic Malignancies (SOHO Brazil) 2022 annual meeting: Myelodysplastic Syndromes
- Post-venetoclax for MDS – case studies after frontline Venetoclax failureBethesda, MD, United States 2022Treatments for MDS and Secondary AML Session
- Practical Guidance on Individualized Patient Care Strategies for Myelodysplastic SyndromesVirtual 2022Indiana University
- The Evolving Treatment Landscape for Higher-Risk Myelodysplastic SyndromeVirtual 2022University of Florida
- Bringing AML approaches to high-risk SMD. Is it working?São Paulo, SP, Brazil 2022Sintoma Hematologic Malignancies (SOHO Brazil) 2022 annual meeting: Myelodysplastic Syndromes
- How is the great barrier of highly resistant myeloid neoplasms being overcome? Learn how it is being doneSão Paulo, SP, Brazil 2022Sintoma Hematologic Malignancies (SOHO Brazil) 2022 annual meeting: Myelodysplastic Syndromes
- When low-risk MDS behaves badlySão Paulo, SP, Brazil 2022Sintoma Hematologic Malignancies (SOHO Brazil) 2022 annual meeting: Myelodysplastic Syndromes
- Post-venetoclax for MDS – case studies after frontline Venetoclax failureBethesda, MD, United States 2022Treatments for MDS and Secondary AML Session, AAMDSIF 2022 BMFD Scientific Symposium
- Practical Guidance on Individualized Patient Care Strategies for Myelodysplastic SyndromesVirtual 2022Clinical Care Options (CCO) CME Talk at Indiana University
- The Evolving Treatment Landscape for Higher-Risk Myelodysplastic Syndrome,Virtual 2022Plexus MDS
- The Evolving Treatment Landscape for Higher-Risk Myelodysplastic SyndromeVirtual 2022Rush University
- Practical Guidance on Individualized Patient Care Strategies for Myelodysplastic SyndromesVirtual 2022Morristown Medical Center
- Point/Counterpoint SessionVirtual 2022Oncology Center of Excellence at the U.S. Food and Drug Administration – Drug Development in Myelodysplastic Syndromes FDA Minisymposium
- Impact of Post-Remission Consolidation Therapy on Outcomes of Haploidentical Hematopoietic Cell Transplantation for Acute Myelogenous LeukemiaVirtual 2022Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR
- The Evolving Treatment Landscape for Higher-Risk Myelodysplastic SyndromeChicago, IL, United States 2022Plexus MDS Talk at Rush University
- Practical Guidance on Individualized Patient Care Strategies for Myelodysplastic SyndromesVirtual 2022Clinical Care Options (CCO) CME Talk at Morristown Medical
- Point/Counterpoint SessionVirtual 2022Oncology Center of Excellence at the U.S. Food and Drug Administration – Drug Development in Myelodysplastic Syndromes FDA Mini Symposium
- Practical Guidance on Individualized Patient Care Strategies for Myelodysplastic SyndromesVirtual 2022Marion L. Shepard Cancer Center
- Understanding HR-MDs to AML spectrumVirtual 2022Saturday AAMDSIF patient meeting
- The Evolving Treatment Landscape for Higher-Risk Myelodysplastic SyndromeVirtual 2022University of Texas Southwestern Medical Center Hematology/Hematopathology Grand Rounds
- Practical Guidance on Individualized Patient Care Strategies for Myelodysplastic SyndromesVirtual 2022Clinical Care Options (CCO) CME Talk at Marion L. Shepard Cancer Center, NC
- Understanding HR-MDs to AML spectrumVirtual 2022Saturday AAMDSIF patient meeting
- The Evolving Treatment Landscape for Higher-Risk Myelodysplastic SyndromeVirtual 2022Plexus MDS Talk at UT Southwestern Medical Center, Dallas, TX Hematology/Hematopathology Grand Rounds
- Highlights of 63rd ASH 2021 Annual Meeting in AMLAmman, Amman Governorate, Jordan 2022Jordan Society of Hematology 9th Annual meeting
- James D Cook Memorial lecture: Myelodysplastic Syndromes: A rapidly changing landscape and evolving use of immune checkpoint inhibitors and highlights from ASH 2021 in MDS and AMLVirtual 2022The University of Kansas ASH Review: Current Updates in Hematologic Diseases
- Myelodysplastic Syndromes: A rapidly changing landscape and evolving use of immune checkpoint inhibitorsVirtual 2022Indian University Cancer Center Grand Rounds
- MDS session Moderator and presenter: A phase 1 study of Venetoclax in refractory/relapsed MDSVirtual 2022International Workshop on Acute Leukemias
- Highlights of 63rd ASH 2021 Annual Meeting in MDSVirtual 2022International Academy of Clinical Hematology
- A Review of Current and Emerging Treatment Options for Myelodysplastic SyndromesAtlanta, GA, United States 2021Friday Satellite Symposia at the American Society of Hematology 62nd Meeting
- Cost-Effectiveness of Liposomal Cytarabine-Daunorubicin (CPX-351) Compared to Conventional Cytarabine-Daunorubicin Chemotherapy in Acute Myeloid LeukemiaAtlanta, GA, United States 2021American Society of Hematology 62nd Meeting
- Oral Decitabine/Cedazuridine in Patients with Lower Risk Myelodysplastic Syndrome: A Longer-Term Follow-up of from the Ascertain StudyAtlanta, GA, United States 2021American Society of Hematology 62nd Meeting
- Session Moderator, Myelodysplastic Syndromes – Clinical and Epidemiological: Low Risk Myelodysplastic Syndrome Prognosis and TreatmentAtlanta, GA, United States 2021American Society of Hematology 62nd Meeting
- Survival of Mantle Cell Lymphoma in the Era of Bruton Tyrosine Kinase Inhibitors: A Population-Based AnalysisAtlanta, GA, United States 2021American Society of Hematology 62nd Meeting
- Venetoclax Plus Azacitidine (VEN-AZA) Vs. Intensive Chemotherapy (IC) As Induction for Patients with Acute Myeloid Leukemia (AML): Retrospective Analysis of an Electronic Medical Records (EMR) Database in the United StatesAtlanta, GA, United States 2021American Society of Hematology 62nd Meeting
- Contemporary “Real World” Molecular Testing and Tyrosine Kinase Inhibitor Adherence Patterns Among Older Pts with Chronic Myeloid Leukemia in the United StatesAtlanta, GA, United States 2021American Society of Hematology 62nd Meeting
- Evaluating Complete Remission with Incomplete Hematologic Recovery (CRh) As a Response Criterion in Myelodysplastic Syndromes (MDS)Atlanta, GA, United States 2021American Society of Hematology 62nd Meeting
- Health-Related Quality of Life (HRQoL) during Treatment with Enasidenib (ENA) Plus Azacitidine (AZA) in Patients with Newly Diagnosed Mutant IDH2 (mIDH2) Acute Myeloid Leukemia (AML) Not Eligible for Intensive Chemotherapy (IC)Atlanta, GA, United States 2021Society of Hematology 62nd Meeting
- Outcomes for Patients with Late-Stage Mutant-IDH2 (mIDH2) Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) Treated with Enasidenib Vs Other Lower-Intensity Therapies in the Randomized, Phase 3 IDHentify TrialAtlanta, GA, United States 2021American Society of Hematology 62nd Meeting
- Analysis of Duration of Response, Exposure-Adjusted Safety and Progression to Acute Myeloid Leukemia (AML) for Patients with Lower-Risk Myelodysplastic Syndromes (LR-MDS) Receiving Luspatercept in the MEDALIST StudyAtlanta, GA, United States 2021American Society of Hematology 62nd Meeting
- Venetoclax and Azacitidine in the Treatment of Patients with Relapsed/Refractory Myelodysplastic SyndromeAtlanta, GA, United States 2021American Society of Hematology 62nd Meeting
- Clonal Compositions Involving Epigenetic Regulator Gene Mutations in Clonal Hematopoiesis, Clonal Cytopenias of Undetermined Significance and Chronic Myelomonocytic LeukemiaAtlanta, GA, United States 2021Hematology 62nd Meeting
- Outcome with Intensive Chemotherapy Compared to Hypomethylating Agent- Based Induction in Patients Aged 70 Years or Older with Newly Diagnosed Favorable Risk Acute Myeloid LeukemiaAtlanta, GA, United States 2021Hematology 62nd Meeting
- Characteristics and Clinical Outcome of Patients with Clonal Cytopenias of Undetermined Significance: A Large Retrospective Multi-Center International StudyAtlanta, GA, United States 2021American Society of Hematology 62nd Meeting
- Evaluation of International Working Group 2006 Response Criteria in Patients with Higher-Risk Myelodysplastic Syndromes (HR-MDS) Treated with Hypomethylating Agent Monotherapy in the Frontline SettingAtlanta, GA, United States 2021American Society of Hematology 62nd Meeting
- Immune and Epigenetic Landscape of TP53-mutated Acute Myeloid Leukemia (AML) and Higher-Risk Myelodysplastic Syndromes (HR-MDS)Atlanta, GA, United States 2021American Society of Hematology 62nd Meeting
- Changes in Multiple Myeloma Treatment Patterns during the Early COVID-19 Pandemic PeriodAtlanta, GA, United States 2021American Society of Hematology 62nd Meeting
- Predictive Biomarkers of Response to the Polo-like Kinase 1 (PLK1) Inhibitor, Onvansertib, in Combination with Decitabine in Relapsed or Refractory Acute Myeloid Leukemia (R/R AML)Atlanta, GA, United States 2021American Society of Hematology 62nd Meeting
- Minimal Toxicity Seen When Pembrolizumab Is Added to Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease: Early Results from an Ongoing Phase II Trial (ECOG-ACRIN EA9171)Atlanta, GA, United States 2021American Society of Hematology 62nd Meeting
- Overall Survival and Progression-Free Survival of Patients Following Luspatercept Treatment in the MEDALIST TrialVirtual 2021American Society of Hematology Annual Meeting
- Venetoclax and Azacitidine in the Treatment of Patients with Relapsed/Refractory Myelodysplastic SyndromeAtlanta, GA, United States 2021American Society of Hematology 63rd Meeting
- Novel therapies for MDSVirtual 2021Mumbai Hematology Group Seminar Series
- Novel therapies for MDSVirtual 2021Mumbai Hematology Group Seminar Series
- Session Chair, Acute Myeloid LeukemiaBeirut, Beirut Governorate, Lebanon 202130th Symposium of the International Association for Comparative Research on Leukemia and Related Diseases (IACRLRD)
- Application of Individualized Treatment for MDS: Expert Guidance for Clinical PracticeVirtual 2021Clinical Care Options CME
- Application of Individualized Treatment for MDS: Expert Guidance for Clinical PracticeVirtual 2021Clinical Care Options CME
- Immune checkpoint inhibitors in MDSVirtual 202116th International Congress on Myelodysplastic Syndromes (MDS 2021)
- Reflective Case-Based Oncology Collective™: Translating Recent Evidence to the Real-World Management of Myelodysplastic SyndromesVirtual 2021PER CME
- Progress in MDS and evolving use of immune checkpoint inhibitionNew York, NY, United States 2021New York University Langone Health
- Phase 3 Verona Study Assessing the Safety and Efficacy of Venetoclax with Azacitidine in Patients with Newly Diagnosed Higher-Risk Myelodysplastic SyndromesVirtual 202116th International Congress on Myelodysplastic Syndromes (MDS 2021)
- Hospitalization and Emergency Room Visits Among Patients with Higher-Risk Myelodysplastic Syndromes by Hypomethylating Agent UseVirtual 202116th International Congress on Myelodysplastic Syndromes (MDS 2021)
- STIMULUS MDS-US Trial in Progress: Evaluating Sabatolimab in Combination with Hypomethylating Agents (HMAs) in Patients with Intermediate-, High-, or Very High–Risk Myelodysplastic Syndromes (MDS)Virtual 2021Society of Hematologic Oncology (SOHO) Annual Meeting
- Prolonged survival observed in 133 MDS patients treated with oral decitabine/cedazuridineVirtual 202116th International Congress on Myelodysplastic Syndromes
- Reflective Case-Based Oncology Collective™: Translating Recent Evidence to the Real-World Management of Myelodysplastic SyndromesVirtual 2021PER CME
- Progress in MDS and evolving use of immune checkpoint inhibition,New York, NY, United States 2021New York University Langone Health
- The Therapeutic Revolution in management of Higher risk MDS: A focus on immunotherapyVirtual 2021International Academy of Clinical Hematology
- The Therapeutic Revolution in management of Higher risk MDS: A focus on immunotherapyVirtual 2021International Academy of Clinical Hematology
- Highlights in Hematologic Malignancies: Leukemias, MDS/MPNVirtual 2021ASCO Direct Highlights
- Highlights in Hematologic Malignancies: Leukemias, MDS/MPNVirtual 2021ASCO Direct Highlights
- IMerge: A phase 3 study to evaluate imetelstat in transfusion-dependent subjects with IPSS low or intermediate-1 risk myelodysplastic syndromes that are relapsed/refractory to erythropoiesis-stimulating agent treatmentVirtual 2021American Society of Clinical Oncology Annual Meeting
- Disparity in utilization of multiagent therapy for acute promyelocytic leukemia (APL): A large National Cancer Database (NCDB) analysisVirtual 2021American Society of Clinical Oncology Annual Meeting
- Predictors of hypomethylating agent discontinuation among patients with higher-risk myelodysplastic syndromesVirtual 2021American Society of Clinical Oncology Annual Meeting
- Phase 3 VERONA study of venetoclax with azacitidine to assess change in complete remission and overall survival in treatment-naïve higher-risk myelodysplastic syndromesVirtual 2021American Society of Clinical Oncology Annual Meeting
- Outcomes of allogeneic hematopoietic cell transplantation in patients with myelofibrosis: A systematic review and meta-analysisVirtual 2021American Society of Clinical Oncology Annual Meeting
- Venetoclax in HR-MDSVirtual 2021EHA 2021 Annual Meeting, Near future in HR-MDS treatment session
- Venetoclax in HR-MDS, invited talk in Near future in HR-MDS treatment sessionVirtual 2021EHA 2021 Annual Meeting
- Novel Agents for Treatment of MDS on the HorizonVirtual 2021MPN-AML United States Virtual Focus Meeting
- Is there a role for post-transplant maintenance therapy in AML?Virtual 20212021 Charlotte Hematologic Malignancies Congress
- Is there a role for post-transplant maintenance therapy in AML?Virtual 20212021 Charlotte Hematologic Malignancies Congress
- Novel agents for treatment of MDS on the horizonVirtual 2021MPN-MDS-AML US Virtual Focus 2021
- Management of Older Patients with AML: A Rapidly Changing LandscapeVirtual 2021Mumbai Hematology Group
- Management of older patients with AML: A rapidly changing landscapeVirtual 2021Mumbai Hematology Group
- A Retrospective Analysis From Patients Treated in The MEDALIST Study: Safety and Efficacy Of Luspatercept Treatment In Patients With Myelodysplastic Syndrome/Myeloproliferative overlapVirtual 2021British Society for Haematology Annual Scientific Meeting
- Update on AML and MDS from the ASH 62nd Annual MeetingVirtual 2021The 8th Annual Meeting of Jordanian Society of Hematology
- Approaches to Initial Treatment of High-Risk MDSVirtual 2021Great Debates & Updates in Hematologic Malignancies Conference
- Is Low Risk MDS Really Low Risk?Virtual 2021Great Debates & Updates in Hematologic Malignancies Conference
- COVID-19 in hematopoietic cell transplant recipients: a CIBMTR studyVirtual 2021Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR
- Updates in AML and MDS from the ASH 62nd Annual Meeting.Virtual 2021The 8th Annual Meeting of Jordanian Society of Hematology
- Approaches to Initial Treatment of High-Risk MDSVirtual 2021Great Debates and Updates in Hematologic Malignancies Annual CME meeting
- Is Low Risk MDS Really Low Risk?Virtual 2021Great Debates and Updates in Hematologic Malignancies Annual CME meeting
- Highlights from ASH 2020 in AML, MDS and MPNVirtual 2021Cardinal Health Specialty Solutions Oncology Virtual Summit
- Update of Immunotherapy in Myeloid MalignanciesVirtual 20205th Annual International Congress on Immunotherapies in Cancer: Focus on Practice-Changing Application
- Comparative Results of Azacitidine and Decitabine from a Large Prospective Phase 3 Study in Treatment Naive Patients with Acute Myeloid Leukemia Not Eligible for Intensive ChemotherapyVirtual 2020American Society of Hematology 62nd Meeting
- The STIMULUS Program: Clinical Trials Evaluating Sabatolimab (MBG453) Combination Therapy in Patients (Pts) with Higher-Risk Myelodysplastic Syndromes (HR-MDS) or Acute Myeloid Leukemia (AML)Virtual 2020American Society of Hematology 62nd Meeting
- Blast MRD AML-1 Trial: Blockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia (AML) 1- an Investigator-Initiated, CTEP-Sponsored, Randomized Phase 2 Study of the Anti-PD-1 Antibody Pembrolizumab in Combination with Conventional Intensive Chemotherapy (IC) As Frontline Therapy in Patients with Acute Myeloid Leukemia (AML)Virtual 2020American Society of Hematology 62nd Meeting
- Updated Analyses of a Phase 1b/2 Study of Onvansertib, a PLK1 Inhibitor, in Combination with Decitabine in Patients with Relapsed or Refractory Acute Myeloid LeukemiaVirtual 2020American Society of Hematology 62nd Meeting
- Blast MRD CML 1 Trial: Blockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease (MRD) in Chronic Myeloid Leukemia (CML)- a Phase II Study of Adding the Anti-PD-1 Pembrolizumab to Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease: A Trial of the ECOG-ACRIN Cancer Research Group (EA9171)Virtual 2020American Society of Hematology 62nd Meeting
- A Phase 1b Study Evaluating the Safety and Efficacy of Venetoclax in Combination with Azacitidine for the Treatment of Relapsed/Refractory Myelodysplastic SyndromeVirtual 2020American Society of Hematology 62nd Meeting
- Blast MRD AML-2: Blockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease (MDR) in Acute Myeloid Leukemia (AML) 2- a Randomized Phase 2 Study of the Venetoclax, Azacitidine, and Pembrolizumab Versus Venetoclax and Azacitidine As First Line Therapy in Older Patients with AML Who Are Ineligible or Who Refuse Intensive ChemotherapyVirtual 2020American Society of Hematology 62nd Meeting
- Streamline – Retrospective Cohort Study of Relapsed or Refractory (R/R) FLT3-Mutated Acute Myeloid Leukemia (AML): Real-World Treatment, Testing Patterns, and OutcomesVirtual 2020American Society of Hematology 62nd Meeting
- The Direct Medical Costs of Treatment Discontinuation Among Higher-Risk Myelodysplastic Syndrome Patients Receiving Hypomethylating AgentsVirtual 2020American Society of Hematology 62nd Meeting
- Comparison of Gilteritinib and Salvage Chemotherapy in FLT3-Mutated Acute Myeloid Leukemia on the Number Needed to Treat for Various Clinical Outcomes: A Secondary Analysis of the Admiral TrialVirtual 2020American Society of Hematology 62nd Meeting
- Under-Use of Hypomethylating Agents in Patients with Higher-Risk Myelodysplastic Syndrome in the United States: A Large Population-Based AnalysisVirtual 2020American Society of Hematology 62nd Meeting
- Trial in Progress: Glad-AML – a Randomized, Phase 2 Trial of Glasdegib with Two Standard Decitabine Regimens for Older Patients with Newly-Diagnosed, Poor-Risk Acute Myeloid LeukemiaVirtual 2020American Society of Hematology 62nd Meeting
- Feasibility of Peri-Transfusion Quality of Life Assessment for Patients with Myelodysplastic SyndromesVirtual 2020American Society of Hematology 62nd Meeting
- Clinical Efficacy and Safety of Oral Decitabine/Cedazuridine in 133 Patients with Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)Virtual 2020American Society of Hematology 62nd Meeting
- Safety and Efficacy of Maintenance Treatment Following Allogeneic Hematopoietic Cell Transplant in Acute Myeloid Leukemia and Myelodysplastic Syndrome – a Systematic Review and Meta-AnalysisVirtual 2020American Society of Hematology 62nd Meeting
- Practice Patterns and Real-Life Outcomes for Patients with Acute Promyelocytic LeukemiaVirtual 2020American Society of Hematology 62nd Meeting
- Gilteritinib Remains Clinically Active in Relapsed/Refractory FLT3 Mutated AML Previously Treated with FLT3 inhibitorsVirtual 2020American Society of Hematology 62nd Meeting
- Oncologist Sub-Specialization, Care Setting, and Multiple Myeloma Treatment and OutcomesVirtual 2020American Society of Hematology 62nd Meeting
- Racial and Ethnic Disparities Have a Significant Impact on the Outcomes of Patients with Myelodysplastic Syndromes: A Population-Based StudyVirtual 2020American Society of Hematology 62nd Meeting
- Molecular Characterization of Clinical Response and Relapse in Patients with IDH1-Mutant Newly Diagnosed Acute Myeloid Leukemia Treated with Ivosidenib and AzacitidineVirtual 2020American Society of Hematology 62nd Meeting
- Efficacy and Safety of Luspatercept Treatment in Patients with Myelodysplastic Syndrome/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T): A Retrospective Analysis from the Medalist StudyVirtual 2020American Society of Hematology 62nd Meeting
- Contemporary Practice Patterns of Tyrosine Kinase Inhibitor Use Among Older Patients with Chronic Myeloid Leukemia in the United StatesVirtual 2020American Society of Hematology 62nd Meeting
- Predictors of Tyrosine Kinase Inhibitor Use Among Older Patients with Chronic Myeloid Leukemia in the United StatesVirtual 2020American Society of Hematology 62nd Meeting
- Racial and Ethnic Disparities Have a Significant Impact on the Outcomes of Patients with Myelodysplastic Syndromes: A Population-Based StudyVirtual 2020American Society of Hematology 62nd meeting
- LONGER-TERM RED BLOOD CELL (RBC) TRANSFUSION REDUCTION IN THE PHASE 3 MEDALIST STUDY OF LUSPATERCEPT IN PATIENTS WITH LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS) WITH RING SIDEROBLASTS (RS)Virtual 2020European Hematology Association Annual Meeting
- Update of Immunotherapy in MyeloidVirtual 20205th Annual International Congress on Immunotherapies in Cancer™: Focus on Practice-Changing Application
- Assessment of Longer-Term Efficacy, Safety, and Haematological Improvement in the Phase 3, Randomised, Double-Blind, Placebo-Controlled MEDALIST Trial of Luspatercept to Treat Anaemia in Patients with Lower-Risk Myelodysplastic Syndromes with Ring Sideroblasts Who Require Red Blood Cell TransfusionsVirtual 2020British Society of Haematology Annual Meeting
- Luspatercept Significantly Reduces Red Blood Cell Transfusion Burden, Regardless of Gene Mutation Frequency, Spectrum, and Prognostic Significance, Among Patients With Lower-Risk Myelodysplastic Syndromes Enrolled in the MEDALIST TrialVirtual 2020British Society of Haematology Annual Meeting
- Targeting BCL-2 in MDSVirtual 2020Society of Hematologic Oncology (SOHO) Annual Meeting
- Next Questions: Acute Myeloid LeukemiaVirtual 2020Society of Hematologic Oncology (SOHO) Annual Meeting
- Glasdegib in Combination with Azacitidine in Patients with Untreated Higher-Risk Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia: Effects on Marrow Recovery and Transfusion IndependenceVirtual 2020Society of Hematologic Oncology (SOHO) Annual Meeting
- Assessment of Dose-Dependent Response to Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes (LR-MDS) with Ring Sideroblasts (RS) in the Phase 3 MEDALIST TrialVirtual 2020Society of Hematologic Oncology (SOHO) Annual Meeting
- Effects of Luspatercept on Serum Ferritin in Patients with Lower-Risk Myelodysplastic Syndromes (LR-MDS) with Ring Sideroblasts (RS) in the Phase 3 MEDALIST TrialVirtual 2020Society of Hematologic Oncology (SOHO) Annual Meeting
- The STIMULUS Clinical Trial Program: Evaluating Combination Therapy with MBG453 in Patients with Higher-Risk Myelodysplastic Syndrome (HR-MDS) or Acute Myeloid LeukemiaVirtual 2020Society of Hematologic Oncology (SOHO) Annual Meeting
- Health-Related Quality of Life in Patients with Untreated Higher-Risk Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia Receiving Glasdegib + AzacitidineVirtual 2020Society of Hematologic Oncology (SOHO) Annual Meeting
- Longer-Term RBC Transfusion Reduction in the Phase 3 MEDALIST Study of Luspatercept in Patients with Lower-Risk MDS (LR-MDS) with Ring Sideroblasts (RS)Virtual 2020Society of Hematologic Oncology (SOHO) Annual Meeting
- A PHASE 1B STUDY EVALUATING THE SAFETY AND EFFICACY OF VENETOCLAX IN COMBINATION WITH AZACITIDINE FOR THE TREATMENT OF RELAPSED/REFRACTORY MYELODYSPLASTIC SYNDROMEVirtual 2020European Hematology Association Annual Meeting
- COMPARATIVE RESULTS OF AZACITIDINE AND DECITABINE FROM A LARGE PROSPECTIVE PHASE 3 STUDY IN TREATMENT NAÏVE ACUTE MYELOID LEUKEMIA (TN-AML) NOT ELIGIBLE FOR INTENSIVE CHEMOTHERAPYVirtual 2020European Hematology Association Annual Meeting
- THE STIMULUS CLINICAL TRIAL PROGRAM: EVALUATING COMBINATION THERAPY WITH MBG453 IN PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROME (HR-MDS) OR ACUTE MYELOID LEUKEMIA (AML)Virtual 2020European Hematology Association Annual Meeting
- UPDATED ANALYSES OF A PHASE 1B/2 STUDY OF ONVANSERTIB, A PLK1 INHIBITOR, IN COMBINATION WITH DECITABINE IN PATIENTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIAVirtual 2020European Hematology Association Annual Meeting
- GLASDEGIB PLUS AZACITIDINE IN PATIENTS WITH UNTREATED HIGHER-RISK MYELODYSPLASTIC SYNDROMES, ACUTE MYELOID LEUKEMIA AND CHRONIC MYELOMONOCYTIC LEUKEMIA: MARROW RECOVERY AND TRANSFUSION INDEPENDENCEVirtual 2020European Hematology Association Annual Meeting
- RESULTS FROM A PHASE 1 DOSE-FINDING STUDY OF CC-90009, A CEREBLON E3 LIGASE MODULATOR AND FIRST-IN-CLASS GSPT1 DEGRADER, IN PATIENTS (PTS) WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA (RR AML)Virtual 2020European Hematology Association Annual Meeting
- CLINICAL BENEFIT OF LUSPATERCEPT IN PATIENTS WITH LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS) AND HIGH TRANSFUSION BURDEN (HTB) IN THE PHASE 3 MEDALIST STUDYVirtual 2020European Hematology Association Annual Meeting
- HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH UNTREATED HIGHER-RISK MYELODYSPLASTIC SYNDROMES, ACUTE MYELOID LEUKEMIA, AND CHRONIC MYELOMONOCYTIC LEUKEMIA RECEIVING GLASDEGIB + AZACITIDINEVirtual 2020European Hematology Association Annual Meeting
- PHARMACODYNAMIC (PD) RESPONSES TO CC-90009, A NOVEL CEREBLON E3 LIGASE MODULATOR (CELMOD), IN A PHASE 1 DOSE-ESCALATION STUDY IN RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA (RR AML)Virtual 2020European Hematology Association Annual Meeting
- EFFECTS OF LUSPATERCEPT ON SERUM FERRITIN IN PATIENTS (PTS) WITH LOWER-RISK MYELODYSPLASTIC SYNDROMES (MDS) WITH RING SIDEROBLASTS (RS) IN THE PHASE 3 MEDALIST TRIALVirtual 2020European Hematology Association Annual Meeting
- ASSESSMENT OF DOSE-DEPENDENT RESPONSE TO LUSPATERCEPT IN PATIENTS (PTS) WITH LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS) WITH RING SIDEROBLASTS IN THE PHASE 3 MEDALIST TRIALVirtual 2020European Hematology Association Annual Meeting
- ENASIDENIB PLUS AZACITIDINE SIGNIFICANTLY IMPROVES COMPLETE REMISSION AND OVERALL RESPONSE RATES VERSUS AZACITIDINE MONOTHERAPY IN MUTANT-IDH2 NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (ND-AML)Virtual 2020European Hematology Association Annual Meeting
- CLINICAL OUTCOMES OF OLDER PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) RECEIVING HYPOMETHYLATING AGENTS: A LARGE POPULATION-BASED STUDY IN THE UNITED STATESVirtual 2020European Hematology Association Annual Meeting
- PATTERNS OF CARE AND CLINICAL OUTCOMES WITH CYTARABINE-ANTHRACYCLINE INDUCTION CHEMOTHERAPY FOR AML PATIENTS IN THE USVirtual 2020European Hematology Association Annual Meeting
- EPIGENETIC AND IMMUNOMODULATORY EFFECTS OF AZACITIDINE (AZA) IN COMBINATION WITH THE ANTI-PD-L1 DURVALUMAB (DURVA) IN AML AND MDS: RESULTS FROM A LARGE, INTERNATIONAL, RANDOMIZED PHASE 2 STUDYVirtual 2020European Hematology Association Annual Meeting
- FACTORS ASSOCIATED WITH HYPOMETHYLATING AGENTS USE IN PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROME (HR-MDS)Virtual 2020European Hematology Association Annual Meeting
- Glasdegib in combination with azacitidine (AZA) in patients (pts) with untreated higher-risk myelodysplastic syndromes (MDS), acute myeloid leukemia (AML) and chronic myelomonocytic leukemia (CMML): Effects on marrow recovery and transfusion independenceVirtual 2020American Society of Clinical Oncology Annual Meeting
- Clinical benefit of luspatercept in patients (pts) with lower-risk MDS (LR-MDS) and high transfusion burden in the phase III MEDALIST studyVirtual 2020American Society of Clinical Oncology Annual Meeting
- Health-related quality of life (HRQoL) in patients with untreated higher-risk myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), and chronic myelomonocytic leukemia (CMML) receiving glasdegib + azacitidine (AZA)Virtual 2020American Society of Clinical Oncology Annual Meeting
- Effect of enasidenib (ENA) plus azacitidine (AZA) on complete remission and overall response versus AZA monotherapy in mutant-IDH2 (mIDH2) newly diagnosed acute myeloid leukemia (ND-AML)Virtual 2020American Society of Clinical Oncology Annual Meeting
- Longer-term RBC transfusion reduction in the phase III MEDALIST study of luspatercept in patients (pts) with lower-risk MDS with ring sideroblasts (RS)Virtual 2020American Society of Clinical Oncology Annual Meeting
- Multiple myeloma (MM) therapy within a Medicare insured patient population: Role of initial care setting and socioeconomic statusVirtual 2020American Society of Clinical Oncology Annual Meeting (Virtual)
- Assessment of Longer-Term Efficacy, Safety, and Haematological Improvement in the Phase 3, Randomised, Double-Blind, Placebo-Controlled MEDALIST Trial of Luspatercept to Treat Anaemia in Patients with Lower-Risk Myelodysplastic Syndromes with Ring Sideroblasts Who Require Red Blood Cell TransfusionsBirmingham, England, United Kingdom 2020British Society for Haematology 60th Annual Scientific Meeting
- Luspatercept Significantly Reduces Red Blood Cell Transfusion Burden, Regardless of Gene Mutation Frequency, Spectrum, and Prognostic Significance, Among Patients With Lower-Risk Myelodysplastic Syndromes Enrolled in the MEDALIST TrialBirmingham, England, United Kingdom 2020British Society for Haematology 60th Annual Scientific Meeting
- MDS & AMLVirtual 2020Stony Brook University Cancer Center Special Seminar
- Secondary AML Updates from ASH ’19Virtual 2020Aplastic Anemia and MDS International Foundation
- Immune Checkpoint Blockade in Myeloid MalignanciesVirtual 2020Massey Cancer Center at Virginia Commonwealth University
- Staying Ahead of the Curve: New Therapeutic Agents in AMLTroy, MI, United States 20201955 AML Small-Group Roundtable
- Staying Ahead of the Curve: New Therapeutic Agents in AMLBeverly Hills, CA, United States 20201955 AML Small-Group Roundtable, Spire Learning
- Patterns of Care and Clinical Outcomes with 7+3 Induction Chemotherapy for Patients (pts) with Acute Myeloid Leukemia (AML) in the United States (US): A Large Population-Based StudyOrlando, FL, United States 2019American Society of Hematology 61st meeting
- 2706 High Rate of IDH1 Mutation Clearance and Measurable Residual Disease Negativity in Patients with IDH1-Mutant Newly Diagnosed Acute Myeloid Leukemia Treated with Ivosidenib (AG-120) and AzacitidineOrlando, FL, United States 2019American Society of Hematology 61st meeting
- A Phase 1b Study of Glasdegib in Combination with Azacitidine in Patients with Untreated Higher-Risk Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic LeukemiaOrlando, FL, United States 2019American Society of Hematology 61st meeting
- Phase II Trial of Vosaroxin and Infusional Cytarabine for Frontline Treatment of Acute Myeloid LeukemiaOrlando, FL, United States 2019American Society of Hematology 61st meeting
- Safety, Efficacy and Biomarker Analysis of a Phase 1b/2 Study of Onvansertib (ONV), a Polo-like Kinase 1 (PLK1) Inhibitor, in Combination with Low-Dose Cytarabine (LDAC) or Decitabine (DEC) in Patients (pts) with Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)Orlando, FL, United States 2019American Society of Hematology 61st meeting
- Clinical Activity of CC-90009, a Cereblon E3 Ligase Modulator and First-in-Class GSPT1 Degrader, as a Single Agent in Patients with Relapsed or Refractory Acute Myeloid Leukemia (R/R AML): First Results from a Phase I Dose-Finding StudyOrlando, FL, United States 2019Oral Presentation in American Society of Hematology 61st meeting
- Incidence and Risk Factors of Second Malignancies Among Medicare Beneficiaries with Newly-Diagnosed Philadelphia Chromosome-Negative Classical Myeloproliferative Neoplasms Receiving Cytoreductive Therapy with HydroxyureaOrlando, FL, United States 2019American Society of Hematology 61st meeting
- Immune Checkpoint Inhibitor Therapy for Acute Myeloid Leukemia and Higher-Risk Myelodysplastic Syndromes: A Single-Center ExperienceOrlando, FL, United States 2019American Society of Hematology 61st meeting
- A Phase I Study of CC-90002, a Monoclonal Antibody Targeting CD47, in Patients with Relapsed and/or Refractory (R/R) Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndromes (MDS): Final ResultsOrlando, FL, United States 2019American Society of Hematology 61st meeting
- The Impact of the 2011 European Leukemianet (ELN) Guidelines for Philadelphia Chromosome-Negative Classical Myeloproliferative Neoplasms on Therapeutic Phlebotomy and Hydroxyurea Use in Patients with Polycythemia Vera and Essential ThrombocythemiaOrlando, FL, United States 2019American Society of Hematology 61st meeting
- Pharmacodynamic Responses to CC-90009, a Novel Cereblon E3 Ligase Modulator, in a Phase I Dose-Escalation Study in Relapsed or Refractory Acute Myeloid Leukemia (R/R AML)Orlando, FL, United States 2019American Society of Hematology 61st meeting
- Enasidenib Plus Azacitidine Significantly Improves Complete Remission and Overall Response Compared with Azacitidine Alone in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) with Isocitrate Dehydrogenase 2 (IDH2) Mutations: Interim Phase II Results from an Ongoing, Randomized StudyOrlando, FL, United States 2019American Society of Hematology 61st meeting
- Clinical Outcomes of Older Patients (pts) with Acute Myeloid Leukemia (AML) Receiving Hypomethylating Agents (HMAs): A Large Population-Based Study in the United StatesOrlando, FL, United States 2019American Society of Hematology 61st meeting
- Assessment of Longer-Term Efficacy and Safety in the Phase 3, Randomized, Double-Blind, Placebo-Controlled MEDALIST Trial of Luspatercept to Treat Anemia in Patients (Pts) with Revised International Prognostic Scoring System (IPSS-R) Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) with Ring Sideroblasts (RS) Who Require Red Blood Cell (RBC) TransfusionsOrlando, FL, United States 2019American Society of Hematology 61st meeting
- Efficacy and Safety of Azacitidine (AZA) in Combination with the Anti-PD-L1 Durvalumab (durva) for the Front-Line Treatment of Older Patients (pts) with Acute Myeloid Leukemia (AML) Who Are Unfit for Intensive Chemotherapy (IC) and Pts with Higher-Risk Myelodysplastic Syndromes (HR-MDS): Results from a Large, International, Randomized Phase 2 StudyOrlando, FL, United States 2019American Society of Hematology 61st meeting
- Pharmacokinetic Exposure Equivalence and Preliminary Efficacy and Safety from a Randomized Cross over Phase 3 Study (ASCERTAIN study) of an Oral Hypomethylating Agent ASTX727 (cedazuridine/decitabine) Compared to IV DecitabineOrlando, FL, United States 2019American Society of Hematology 61st meeting
- Clinical Effectiveness of Hypomethylating Agents (HMAs) and Lenalidomide (Len) in Older Patients (pts) with Refractory Anemia with Ring Sideroblasts: A Large Population-Based Study in the United States (US)Orlando, FL, United States 2019American Society of Hematology 61st meeting
- A Randomized, Double-Blind, Placebo-Controlled, Phase II Study of MBG453 Added to Hypomethylating Agents (HMAs) in Patients (pts) with Intermediate, High, or Very High Risk Myelodysplastic Syndrome (MDS): Stimulus-MDS1Orlando, FL, United States 2019American Society of Hematology 61st meeting
- Cost-Effectiveness Analysis of Gilteritinib Versus Salvage Chemotherapy (SC) for the Treatment of Relapsed or Refractory (R/R) FLT3-Mutated (FLT3mut+) Acute Myeloid Leukemia (AML)Orlando, FL, United States 2019American Society of Hematology 61st meeting
- Clinical Benefit of Glasdegib in Combination with Azacitidine or Low-Dose Cytarabine in Patients with Acute Myeloid LeukemiaOrlando, FL, United States 2019American Society of Hematology 61st meeting
- Understanding and Improving Outcomes of Patients with Myelodysplastic Syndromes at the Patient and Population LevelsZhuhai, Guangdong Province, China 201924th Congress of Chinese Pediatric Society
- Management of Acute Myeloid Leukemia: The Post 2017 EraGuangzhou, Guangdong Province, China 2019Guangzhou Women’s and Children’s Medical Center
- AML Treatment in 2019: Where Are We Now and Where Are We Headed?Estoril, Lisbon, Portugal 2019, 5th International Conference Acute Myeloid Leukemia “Molecular and Translational”: Advances in Biology and Treatment
- Management of Older Patients with AMLHartford, CT, United States 2019Advanced Science Workshop on Myeloid Malignancies
- Management of Lower Risk MDSNew Haven, CT, United States 2019Advanced Science Workshop on Myeloid Malignancies
- Myelodysplastic Syndromes: Understanding and Improving Outcomes at the Individual and Population LevelsBarcelona, CT, Spain 2019Hospital del Mar
- How I Treat Patients with Low Grade Myelodysplastic SyndromeChicago, IL, United States 20192019 ASH Meeting on Hematologic Malignancies
- Understanding & Improving Outcomes of Patients with MDS at Individual & Population LevelsBoston, MA, United States 2019Boston University Grand Rounds
- Chromosome 1 abnormalities and clinical era of novel agentsChicago, IL, United States 201955th Annual American Society of Clinical Oncology (ASCO) Meeting
- Updates in Myelodysplastic SyndromesNew Haven, CT, United States 2019Leukemia & Lymphoma Society Evening of Education
- Phase Ib safety, preliminary anti-leukemic activity and biomarker analysis of the polo-like kinase 1 (PLK1) inhibitor, onvansertib, in combination with low-dose cytarabine or decitabine in patients with relapsed or refractory acute myeloid leukemiaAtlanta, GA, United States 2019American Association of Cancer Research (AACR) Annual Meeting
- Use of Immune Checkpoint Inhibitors in Myeloid Malignancies: A Promise yet to be FulfilledLos Angeles, CA, United States 2019Great Debates and Updates in Hematology
- How I treat acute leukemia in elderly patientsAmman, Amman Governorate, Jordan 2019Connecting Through Research: The King Hussein Cancer Center’s annual joint conference with the American University of Beirut Medical Center and MD Anderson Cancer Center
- How I treat Myelodysplastic SyndromesAmman, Amman Governorate, Jordan 2019Connecting Through Research: The King Hussein Cancer Center’s annual joint conference with the American University of Beirut Medical Center and MD Anderson Cancer Center
- Incorporation of molecular assessments in risk stratification for myelodysplastic syndromes: Ready for prime time?Seoul, Seoul, South Korea 20192019 Korean Society of Hematology International Conference & 60th Annual Meeting (ICKSH 2019)
- Safety and Clinical Activity of Mutant IDH1 Inhibitor Ivosidenib (IVO; AG-120) in Combination with Azacitidine (AZA) for Newly Diagnosed Acute Myeloid Leukemia (ND AML)Munich, BY, Germany 2019Acute Leukemias XVII Biology and Treatment Strategies
- AML in Older Patients: Are We Exiting the Boulevard of Broken Dreams?Amman, Amman Governorate, Jordan 2019King Hussein Cancer Center
- Myelodysplastic Syndromes: Predicting and Improving Outcomes at the Individual and Population LevelsAmman, Amman Governorate, Jordan 2019University of Jordan
- Impact of Leukapheresis and Time to Chemotherapy on Outcomes of Newly Diagnosed Patients (pts) with Acute Myeloid Leukemia (AML) Presenting with Hyperleukocytosis: An Analysis from a Large International Patient CohortSan Diego, CA, United States 2018American Society of Hematology 60th meeting
- Wide Variation in Use and Interpretation of Gene Mutation Profiling Panels Among Health Care Providers of Patients with Myelodysplastic Syndromes (MDS): Results of a Large Web-Based SurveySan Diego, CA, United States 2018American Society of Hematology 60th meeting
- Does Provider Experience Treating Patients (pts) with Myelodysplastic Syndromes (MDS) Explain Duration of Hypomethylating Agent (HMA) Therapy and Overall Survival (OS)? a Large Population-Based AnalysisSan Diego, CA, United States 2018American Society of Hematology 60th meeting
- Effective Immunomodulation with Pomalidomide Beginning at Early Lymphocyte Recovery during Induction Timed Sequential Therapy (TST) for Acute Myeloid Leukemia (AML) and High-Risk Myelodysplasia (HR-MDS)San Diego, CA, United States 2018American Society of Hematology 60th meeting
- The Medalist Trial: Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Luspatercept to Treat Anemia in Patients with Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) with Ring Sideroblasts (RS) Who Require Red Blood Cell (RBC) TransfusionsSan Diego, CA, United States 2018American Society of Hematology 60th meeting
- Use of Statins, Survival and Incidence of Thrombosis Among Older Adults with Polycythemia Vera: A Population-Based StudySan Diego, CA, United States 2018American Society of Hematology 60th meeting
- Association between Oncologist Ownership of Imaging Facilities and Utilization: An Analysis of Positron-Emission Tomography (PET) Use in Lymphoma Settings with Variable PET UtilitySan Diego, CA, United States 2018American Society of Hematology 60th meeting
- Transfusion Independence in Lower-Risk, Non-del5(q) Myelodysplastic Syndromes (LR-MDS) Among Patients (pts) Initiating Hypomethylating Agents (HMAs) While Receiving Red Blood Cell (RBC) TransfusionsSan Diego, CA, United States 2018American Society of Hematology 60th meeting
- Racial Disparities in the Utilization of Recommended Supportive Care Among Patients with Multiple Myeloma in the United StatesSan Diego, CA, United States 2018American Society of Hematology 60th meeting
- Characteristics, Treatment Patterns and Outcomes Among Newly Diagnosed Patients (pts) with Acute Myeloid Leukemia (AML) Who Present with Hyperleukocytosis: Findings from a Large International Patient CohortSan Diego, CA, United States 2018American Society of Hematology 60th meeting
- Preliminary Safety, Pharmacokinetics (PK) and Pharmacodynamic (PD) Analysis of the Polo-like Kinase-1 (PLK1) Inhibitor PCM-075, in Combination with Low-Dose Cytarabine (LDAC) or Decitabine (D) in Patients with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML)San Diego, CA, United States 2018American Society of Hematology 60th meeting
- Outcomes of Patients with Newly-Diagnosed Acute Myeloid Leukemia and Hyperleukocytosis Who Did Not Undergo Intensive Chemotherapy: Results from a Large International DatabaseSan Diego, CA, United States 2018American Society of Hematology 60th meeting
- Use of Statins, Survival and Incidence of Thrombosis Among Older Adults with Essential Thrombocythemia: A Population-Based StudySan Diego, CA, United States 2018American Society of Hematology 60th meeting
- Managing AML in Elderly Populations: New StandardsSan Diego, CA, United States 2018American Society of Hematology 60th Meeting
- Therapeutic Approach to MDSKandy, CP, Sri Lanka 2018The Annual Academic Session of Sri Lanka College of Haematologists
- Novel Therapeutic Agents in AMLKandy, CP, Sri Lanka 2018The Annual Academic Session of Sri Lanka College of Haematologists
- Myelodysplastic Syndromes: Predicting and Improving Outcomes at the Patient and the Population LevelsPittsburgh, PA, United States 2018Shadyside Hospital, University of Pittsburgh
- An Open-Label Phase 1 Study to Evaluate the Safety and Tolerability of Durvalumab in Patients With Myelodysplastic Syndrome After Treatment With Hypomethylating AgentsStockholm, Stockholm County, Sweden 20182018 EHA Annual Meeting
- A Phase 1b/2 Study of a Selective PLK-1 inhibitor in Acute Myelogenous Leukemia (AML) in combination with Low-Dose Cytarabine or DecitabineChicago, IL, United States 20182018 ASCO Annual Meeting
- Myelodysplastic Syndromes: Predicting and Improving Outcomes at the Patient and the Population LevelsNew York, NY, United States 2018Memorial Sloan Kettering Cancer Center
- Myelodysplastic Syndromes: Predicting and Improving Outcomes at the Patient and the Population LevelsOklahoma City, OK, United States 2018Hematology Oncology Grand Rounds (CME), University of Oklahoma Health Sciences Center
- Newly approved drugs for AMLNew York, NY, United States 2018Great Debates and Updates in Hematologic Malignancies (CME)
- Debate: Clinical Scenarios in AML: Traditional vs. Targeted TherapyNew York, NY, United States 2018Great Debates and Updates in Hematologic Malignancies (CME)
- Best Practices in the Implementation of Clinical Practice Guidelines for the Treatment of Patients with Myelodysplastic Syndromes and Iron OverloadVirtual 20182018 NCCN General Poster Sessions
- Myelodysplastic Syndromes: Predicting and Improving Outcomes at the Patient and the Population LevelsNew York, NY, United States 2018Memorial Sloan Kettering Cancer Center
- Myelodysplastic SyndromesBalikpapan, East Kalimantan, Indonesia 20182018 Highlights of ASH in Asia – Pacific Program
- Myelodysplastic Syndromes: Predicting and Improving outcomes at the patient and the population levelsAmman, Amman Governorate, Jordan 2018Medical Grand Rounds, King Hussein Cancer Center
- An update on the diagnosis and risk stratification of myelodysplastic syndromesAmman, Amman Governorate, Jordan 20185th International Jordanian Society of Hematology Conference
- Risk adaptive management of myelodysplastic syndromesAmman, Amman Governorate, Jordan 20185th International Jordanian Society of Hematology Conference
- A Systematic Review and Meta-Analysis of the Effect of Iron Chelation Therapy on Survival of Patients with Lower-Risk Myelodysplastic SyndromesPuebla, Pue., Mexico 2018International Conference on Health and Migration
- A Systematic Review and Meta-Analysis of the Effect of Iron Chelation Therapy on Survival of Patients with Lower-Risk Myelodysplastic SyndromesPuebla, Pue., Mexico 2018International Conference on Health and Migration
- Myelodysplastic SyndromesNew York, NY, United States 2018Highlights of ASH in North America
- Myelodysplastic SyndromesMiami, FL, United States 2018Highlights of ASH in North America
- Myelodysplastic SyndromesSan Francisco, CA, United States 2018Highlights of ASH in North America
- Phase II trial of Vosaroxin and Infusional Cytarabine for Frontline Treatment of Acute Myeloid Leukemia (VITAL) Patients Eligible for Intensive chemotherapy: A Planned Interim AnalysisAtlanta, GA, United States 2017American Society of Hematology 59th meeting
- PD-1H (VISTA) Induces Immune Evasion in Acute Myeloid LeukemiaAtlanta, GA, United States 2017American Society of Hematology 59th meeting
- A Systematic Review of the Effect of Iron Chelation Therapy on Survival in Patients with Sickle Cell Disease and β-ThalassemiaAtlanta, GA, United States 2017American Society of Hematology 59th meeting
- A Systematic Review and Meta-Analysis of the Effect of Iron Chelation Therapy on Survival in Patients with Lower Risk Myelodysplastic SyndromeAtlanta, GA, United States 2017American Society of Hematology 59th meeting
- A Phase 1/2 Study of the Oral Novel JAK1 Inhibitor INCB052793 As Monotherapy and in Combination with Standard Therapies in Patients with Advanced Hematologic MalignanciesAtlanta, GA, United States 2017American Society of Hematology 59th meeting
- Relationship between Hospital Volume and Inpatient Mortality Among Patients Diagnosed with Thrombotic Thrombocytopenic Purpura (TTP) in the United States Session Name: 901. Health Services Research—Non-Malignant Conditions: Consultative HematologyAtlanta, GA, United States 2017American Society of Hematology 59th meeting
- Preliminary Results from an Ongoing Phase 1/2 Study of INCB053914, a Pan-Proviral Integration Sites for Moloney Virus (PIM) Kinase Inhibitor, in Patients with Advanced Hematologic MalignanciesAtlanta, GA, United States 2017American Society of Hematology 59th meeting
- Validation of the Medical Research Council (MRC) and the Leukemia Research Foundation (LRF) Score for Hypomethylating Agents (HMAs) Use in Patients with Relapsed and Refractory Acute Myeloid Leukemia (RR-AML)Atlanta, GA, United States 2017American Society of Hematology 59th meeting
- Hypomethylating Agents (HMAs) in Patients with Relapsed and Refractory Acute Myeloid Leukemia (RR-AML)– Transplant Outcomes Post HMA Therapy in a Large International Patient CohortAtlanta, GA, United States 2017American Society of Hematology 59th meeting
- The Use of Immunosuppressive Therapy (IST) in Patients with the Myelodysplastic Syndromes (MDS): Clinical Outcomes and Their Predictors in a Large International Patient CohortAtlanta, GA, United States 2017American Society of Hematology 59th meeting
- The Impact of Phlebotomy and Hydroxyurea on Survival and Risk of Thrombosis Among Older Patients with Polycythemia VeraAtlanta, GA, United States 2017American Society of Hematology 59th meeting
- The Impact of Hydroxyurea on Survival and Risk of Thrombosis Among Older Patients with Essential ThrombocythemiaAtlanta, GA, United States 2017American Society of Hematology 59th meeting
- Long-Term Survival of Older Patients with Myelodysplastic Syndromes Treated with Hypomethylating Agent Therapy: A Large Population-Based AnalysisAtlanta, GA, United States 2017American Society of Hematology 59th meeting
- Interim Data from a Phase 1 Study Evaluating Pyrrolobenzodiazepine-Based Antibody Drug Conjugate ADCT-402 (Loncastuximab Tesirine) Targeting CD19 for Relapsed or Refractory B-Cell Acute Lymphoblastic LeukemiaAtlanta, GA, United States 2017American Society of Hematology 59th meeting
- Beliefs and Patterns of Practice in the Management of Hyperleukocytosis and Leukostasis Among Health Care Providers for Patients with Acute Leukemia: A Large North American Web-Based SurveyAtlanta, GA, United States 2017American Society of Hematology 59th meeting
- Treatment Sequence of Lenalidomide (LEN) and Hypomethylating Agents (HMAs) and the Impact on Clinical Outcomes for Patients with Myelodysplastic Syndromes (MDS)Atlanta, GA, United States 2017American Society of Hematology 59th meeting
- Counseling Patients (pts) with Higher-Risk Myelodysplastic Syndromes (HR-MDS) Regarding Expected Survival with Azacitidine (aza) Therapy: Are We Using Accurate Estimates?Atlanta, GA, United States 2017American Society of Hematology 59th meeting
- Immunological Correlates of Treatment with the CTLA-4 Inhibitor Ipilimumab in Patients with Refractory Myelodysplastic Syndromes (MDS)Atlanta, GA, United States 2017American Society of Hematology 59th meeting
- The Impact of the Administration Schedule and Mutational Profile on Outcomes of Patients with Relapsed and Refractory Acute Myeloid Leukemia Treated with Hypomethylating Agents: A Large, International, Multi-Center AnalysisAtlanta, GA, United States 2017American Society of Hematology 59th meeting
- A Phase ½ Study of the Oral Novel JAK1 Inhibitor INCB052793 as Monotherapy and in Combination with Standard Therapies in Patients with Advanced Hematologic MalignanciesAtlanta, GA, United States 2017American Society of Hematology 59th Meeting
- Iron Chelation Therapy for MDSPhiladelphia, PA, United States 2017US Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes
- Hypomethylating agent therapy use and survival in older patients with chronic myelomonocytic Leukemia in the United States: A large population-based studyValencia, VC, Spain 2017The 14th International Symposium on Myelodysplastic Syndromes
- Hypomethylating Agent Therapy Use and Survival in Older Patients with Chronic Myelomonocytic Leukemia in USA: A Large Population-Based StudyValencia, VC, Spain 2017The 14th International Symposium on Myelodysplastic Syndromes
- A Phase 1 Trial of Ipilimumab in Patients with Myelodysplastic Syndromes after Hypomethylating Agents FailureAlexandria, VA, United States 20172017 American Society of Clinical Oncology (ASCO)/Conquer Cancer Foundation (CCF) Scientific Career Development Retreat/Workshop
- How Should Molecular Testing Inform Transplant Decisions in MDS or MPN?New York, NY, United States 2017Great Debates & Updates in Hematologic Malignancies
- Myelodysplastic Syndromes: Understanding and Improving Outcomes at the Patient and Population LevelsHackensack, NJ, United States 2017John Theurer Cancer Center
- Hypomethylating agent therapy use and survival in older patients with chronic myelomonocytic Leukemia in the United States: A large population-based studySan Diego, CA, United States 2016American Society of Hematology 58th meeting
- The Use of Hypomethylating Agents (HMAs) in Patients with Relapsed and Refractory Acute Myeloid Leukemia (RR-AML): Clinical Outcomes and Their Predictors in a Large International Patient CohortSan Diego, CA, United States 2016American Society of Hematology 58th meeting
- Cost-Effectiveness Analysis of Consolidation with Brentuximab Vendotin Versus Active Surveillance in Individuals with High-Risk Hodgkin Lymphoma Undergoing High Dose Chemotherapy with Stem Cell RescueSan Diego, CA, United States 2016American Society of Hematology 58th meeting
- Phase 1 Study of Pomalidomide Given at the Time of Early Lymphocyte Recovery after Induction Timed Sequential Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HR-MDS)San Diego, CA, United States 2016American Society of Hematology 58th meeting
- Use of hypomethylating agents in myelodysplastic syndromes: Current approaches and future directionsPuebla, Pue., Mexico 2016Puebla, Mexico
- Progress and innovation in myeloid malignanciesPuebla, Pue., Mexico 2016Puebla, Mexico
- Risk adaptive management of Myelodysplastic SyndromesPuebla, Pue., Mexico 2016Recorded Webcast
- Myelodysplastic syndromes: An update on diagnosis and prognosticationMaya Tecún I, Camp., Mexico 2016Hexpertia: Encuentro de Expertos y Avances Terapeuticos en Hematologia 2016 meeting
- Myelodysplastic syndromes: Current therapeutic approachesMaya Tecún I, Camp., Mexico 2016Hexpertia: Encuentro de Expertos y Avances Terapeuticos en Hematologia 2016 meeting
- Challenging myelodysplastic syndrome casesMaya Tecún I, Camp., Mexico 2016Hexpertia: Encuentro de Expertos y Avances Terapeuticos en Hematologia 2016 meeting,
- North American Cooperative Group Members' Patterns of Blood Products Transfusion for Patients with Acute LeukemiaOrlando, FL, United States 2015American Society of Hematology 57th meeting
- Differential Response to Hypomethylating Agents Based on Sex: A Report on Behalf of the MDS Clinical Research Consortium (MDS CRC)Orlando, FL, United States 2015American Society of Hematology 57th meeting
- Results of a Phase 2 Trial of High Dose Lenalidomide Monotherapy in Patients with Relapsed/Refractory Higher-Risk Myelodysplastic Syndromes or Acute Myeloid Leukemia with Trilineage DysplasiaOrlando, FL, United States 2015American Society of Hematology 57th meeting
- Quality of End-of-Life Care for the Myelodysplastic Syndromes: Findings from a Large National DatabaseOrlando, FL, United States 2015American Society of Hematology 57th meeting
- Comparative Effectiveness of Azacitidine Versus Decitabine Among Older Adults Diagnosed with Higher-Risk Myelodysplastic Syndromes (HR-MDS)Orlando, FL, United States 2015American Society of Hematology 57th meeting
- Myelodysplastic Syndromes and Acute Myeloid Leukemia in Prostate Cancer Patients after Radiotherapy, a Population-Based StudyOrlando, FL, United States 2015American Society of Hematology 57th meeting
- Patterns of Venous Thromboembolism Prophylaxis during Inpatient Treatment of Acute Leukemia: Results of a North American Web-Based SurveyOrlando, FL, United States 2015American Society of Hematology 57th meeting
- Stabilization of myelodysplastic syndromes (MDS) following hypomethylating agent (HMAs) failure using the immune checkpoint inhibitor ipilimumab: A Phase I trialOrlando, FL, United States 2015American Society of Hematology 57th meeting
- Secondary myeloid neoplasms in older women with breast cancer after radiotherapy: A population-based studyOrlando, FL, United States 2015American Society of Hematology 57th meeting
- Disease-specific costs of care and survival among Medicare-enrolled patients with myelodysplastic syndromesOrlando, FL, United States 2015American Society of Hematology 57th meeting
- Current management of acute myeloid leukemia in older patients unfit for intensive ChemotherapyMexico City, CDMX, Mexico 2015Mexico City, Mexico
- An update on the diagnosis and management of myelodysplastic syndromesCuernavaca, Mor., Mexico 2015Cuernavaca, Mexico
- Myelodysplastic Syndromes: Targeting the Immune System for TherapyBuffalo, NY, United States 2015Roswell Park Cancer Institute
- Disease-specific costs of care and survival among Medicare-enrolled patients with myelodysplastic syndromesWashington, DC, United States 2015the 13th International Symposium on Myelodysplastic Syndromes
- Disease-specific costs of care and survival among Medicare-enrolled patients with myelodysplastic syndromesHouston, TX, United States 2015Society of Hematologic Oncology (SOHO) Annual Meeting
- The utility of risk models in predicting outcomes of patients (pts) with higher-risk myelodysplastic syndromes (HR-MDS) treated with hypomethylating agents (HMA)San Francisco, CA, United States 2014American Society of Hematology 56th meeting
- The Prognostic Utility of the Current Risk Models in Predicting Outcomes of Patients (pts) with Higher-Risk Myelodysplastic Syndromes (HR-MDS) Treated with Hypomethylating Agents (HMA)San Francisco, CA, United States 2014American Society of Hematology 56th Meeting
- Myelodysplastic Syndromes: Targeting the Immune System for TherapyAnn Arbor, MI, United States 2014University of Michigan
- The Utility Of Newer Risk Models In Predicting Outcomes Of Patients (pts) With Higher-Risk (HR) Myelodysplastic Syndromes (MDS) Treated With Azacitidine (aza)New Orleans, LA, United States 2013American Society of Hematology 55th meeting
- Application of the Revised IPSS (IPSS-R) and The French Prognostic Score (FPS) To Assess Overall Survival (OS) In Patients (pts) With Myelodysplastic Syndromes (MDS) Treated With Azacitidine (Aza) In a Large North American Intergroup TrialNew Orleans, LA, United States 2013American Society of Hematology 55th meeting
- The Use Of Donor Lymphocyte Infusion (DLI) For Relapse After Related T-Cell Replete HLA-Haploidentical Bone Marrow Transplantation (haploBMT) With Posttransplantation Cyclophosphamide (PTCy)New Orleans, LA, United States 2013American Society of Hematology 55th meeting
- Validation Of a Brief Arsenic Trioxide (ATO)-Based Consolidation Chemotherapy In The Upfront Management Of Acute Promyelocytic Leukemia (APL): Less Anthracycline Exposure and Faster Completion Of Consolidation Therapy With Equivalent SurvivalNew Orleans, LA, United States 2013American Society of Hematology 55th meeting
- Azacitidine With Or Without Entinostat For The Treatment Of Therapy-Related Myeloid Neoplasm: Further Results Of The E1905 North American Leukemia Intergroup Study.New Orleans, LA, United States 2013American Society of Hematology 55th meeting
- Application of the French Prognostic Score to Assess Overall Survival in a US-Based Cohort of Patients Treated with AzacitidineChicago, IL, United States 2013American Society of Clinical Oncology (ASCO) Annual Meeting
- Myelodysplastic syndromes: A changing landscape and therapeutic opportunitiesBaltimore, MD, United States 2013Johns Hopkins University
- Application of the French Prognostic Score to Assess Overall Survival in a US-Based Cohort of Patients Treated with AzacitidineBerlin, BE, Germany 201312th MDS International Symposium
- Effect of availability of oral iron chelation therapy on initiation, duration, and dose adequacy in patients with myelodysplastic syndromes and transfusional iron overloadBerlin, BE, Germany 2013MDS International Symposium 2013
- HIV-associated peripheral T-cell lymphoma: a report of two cases with insights into the ongoing propensity for lymphoma in the HAART eraSan Francisco, CA, United States 2013The Annual T-cell Lymphoma Forum
- Deferasirox Is Associated with Reduced Mortality Risk in a Medicare Population with Myelodysplastic SyndromesAtlanta, GA, United States 2012American Society of Hematology (ASH) 54th meeting
- Lenalidomide Performance in the Real World: Patterns of Utilization and Effectiveness in a Medicare Population with Myelodysplastic SyndromesAtlanta, GA, United States 2012American Society of Hematology 54th meeting
- Venous Thromboembolism Prevention Practices Among Health Care Providers Caring for Patients Hospitalized for Hematopoietic Stem Cell Transplantation: An International Web-Based SurveyAtlanta, GA, United States 2012American Society of Hematology 54th meeting
- Utilization Patterns of Iron Chelation Therapy in Transfusion-Dependent Myelodysplastic Syndrome Patients Enrolled in Medicare Part DAtlanta, GA, United States 2012American Society of Hematology 54th meeting
- Medicare Prescription Drug Coverage and Home Use of Erythropoiesis-Stimulating Agents for MDS-Associated Anemia: A Medicare-Database AnalysisAtlanta, GA, United States 2012American Society of Hematology 54th meeting
- Association Between FDA Safety Warnings, CMS Coverage Restrictions and Adherence to Guidelines for ESA Use in Patients with Myelodysplastic SyndromesAtlanta, GA, United States 2012American Society of Hematology 54th meeting
- Lenalidomide Performance in the Real World: Patterns of Utilization and Effectiveness in a Medicare Population with Myelodysplastic SyndromesBerlin, BE, Germany 2012MDS International Symposium 2013
- Haploidentical Hematopoietic Stem Cell Transplant for a Patient with Histiocytic SarcomaSofia, Sofia City Province, Bulgaria 2012European Society of Hematology- European Group for Blood and Marrow Transplantation 16th Training Course on Stem Cell Transplantation
- Impact of a Venous Thromboembolism Prophylaxis “Smart Order Set”: Improved Compliance, Fewer EventsSan Diego, CA, United States 2011American Society of Hematology 53rd meeting
- Escalation Trial of Clofarabine Followed by Escalating Dose of Fractionated Cyclophosphamide in Adults with Relapsed or Refractory Acute LeukemiasSan Diego, CA, United States 2011American Society of Hematology 53rd meeting
- Impact of a Venous Thromboembolism Prophylaxis “Smart Order Set”: Improved Compliance, Fewer EventsSan Diego, CA, United States 2011American Society of Hematology 53rd meeting
- Escalation Trial of Clofarabine Followed by Escalating Dose of Fractionated Cyclophosphamide in Adults with Relapsed or Refractory Acute LeukemiasBaltimore, MD, United States 2011Sidney Kimmel Cancer Center 18th Annual Fellow Research Day
- Gemtuzumab Ozogamicin and Continuous Infusion Cytarabine for Relapsed/Refractory Acute Myeloid Leukemia Prior to Allogeneic Stem Cell Transplantation.San Francisco, CA, United States 2008American Society of Hematology (ASH) 50th meeting
- Frequent Molecular Aberrations in Normal Karyotype (NC) Precursor B-Cell Acute Lymphoblastic Leukemia (pB-ALL) Detected by Comparative Genomic HybridizationAtlanta, GA, United States 2007American Society of Hematology (ASH) 49th meeting
- Intracranial calcifications masquerading as intracranial hemorrhage in a mild hemophiliacRochester, NY, United States 2007University of Rochester, School of Medicine annual city-wide poster competition
- Tumor Lysis Syndrome in Acute Myeloid Leukemia Induction: Validation of Penn Predictive Score of Tumor Lysis Syndrome (PPS-TLS)Rochester, NY, United States 2007Rochester General Hospital annual city-wide poster competition
- Rituximab-Refractory Cryoglobulinemic Nephritis Associated with Disappearance of a Paraprotein and the Appearance of a New IgG Paraprotein in a Patient with SLE and Sjogren’s SyndromeRochester, NY, United States 2007Rochester General Hospital annual city-wide poster competition
- Monosomy 7 in t(9;22)-Negative Cells during Nilotinib Therapy in an Imatinib-Resistant Chronic Myeloid Leukemia CaseRochester, NY, United States 2007Rochester General Hospital annual city-wide poster competition
- First Report of Primary Meningococcal Pericarditis Caused by Meningococcus Serotype Y that Rapidly Evolved into a Pericardial TamponadeRochester, NY, United States 2007Rochester General Hospital annual city-wide poster competition
- Mosaic Turner Syndrome with Minimal Phenotypic Penetrance Diagnosed upon Presentation with Acute Myeloid LeukemiaRochester, NY, United States 2007Rochester General Hospital annual city-wide poster competition
- Intracranial calcifications masquerading as intracranial hemorrhage in a mild hemophiliacRochester, NY, United States 2007Rochester General Hospital annual city-wide poster competition
- Gene Expression Profiling In Normal Karyotype Acute Myeloid Leukemia: Is It The Magical Answer?Rochester, NY, United States 2007Rochester General Hospital
- Crohn’s Disease and Hepatosplenic T-Cell Lymphoma (HSTL): Case Report and Review of the Literature of Splenomegaly and HTSL in Patients with Crohn’s DiseaseRochester, NY, United States 2006Rochester General Hospital annual city-wide poster competition
- A Patient With Coexisting Antiphospholipid Syndrome and Von Willebrand Disease: Does the Bleeding Diathesis Protect Against Thrombosis?Rochester, NY, United States 2006Rochester General Hospital annual city-wide poster competition
- Treatment of Refractory SLE with RituximabRochester, NY, United States 2004University of Rochester School of Medicine annual city-wide poster competition
Honors & Recognition
Award | Awarding Organization | Date |
---|---|---|
Scholar in Clinical Research Award | Leukemia and Lymphoma Society | 2018, 2019, 2020, 2021, 2022, 2023 |
Cancer Clinical Investigator Team Leadership Award | National Cancer Institute | 2018, 2019, 2020 |
The Tito Bastianello Young Investigator Award | The 13th Annual International Symposium on Myelodysplastic Syndromes | 2015 |
Cooper Hematology Young Investigator Award | 2015 | |
Young Investigator Travel Grant | The Society of Oncologic Malignancy | 2015, 2016 |
Young Investigator Award | American Society of Clinical Oncology | 2013, 2014 |
Travel Award | 14th Annual Fellows and the 23rd Mayo Clinic Hematology and Oncology Reviews | 2013 |
Travel Grant | European Group for Blood and Marrow Transplantation | 2013 |
Scholarship Award | European Society of Hematology - European Group for Blood and Marrow Transplantation | 2012 |
Educational Grant | National Comprehensive Cancer Centers Network | 2012 |
Abstract Achievement Award | American Society of Hematology | 2011, 2012, 2013 |
First Place in Original Research Presentation | Rochester General Hospital Annual City-Wide Poster Competition | 2007 |
First Place in Clinical Case Poster and Presentation | University of Rochester School of Medicine Annual City-Wide Poster Competition | 2004 |
Distinguished Academic Performance Award | University of Jordan, College of Medicine | 1998, 2000, 2001 |
Certificate of Honors | Ministry of Education | 1995 |
Professional Service
Organization | Role | Date |
---|---|---|
17th International Congress on Myelodysplastic Syndromes. | Abstract Reviewer | 2023 |
King Hussein Cancer Center Research Conference | Abstract Reviewer | 2022 |
Scientific Research Committee, King Hussein Cancer Center Research Conference | Chair | 2022 |
King Hussein Cancer Center Research Conference | Scientific Director | 2022 - Present |
Yale ASH Highlights Series | Director | 2021 |
Myelodysplastic Syndromes – Clinical and Epidemiological: Low Risk Myelodysplastic Syndrome Prognosis and Treatment, American Society of Hematology 64nd Meeting | Abstract Reviewer | 2021 |
Myelodysplastic Syndromes – Clinical and Epidemiological: Low Risk Myelodysplastic Syndrome Prognosis and Treatment, American Society of Hematology 64nd Meeting | Moderator | 2021 |
30th Symposium of the International Association for Comparative Research on Leukemia and Related Diseases (IACRLRD) | Session Chair | 2021 - Present |
Advanced Science Workshop on Myeloid Malignancies, Yale University | Chair | 2019 |
4th Annual Hematologic Malignancies Symposium, Yale University | Co-Chair | 2019 |
Ward Teaching Rounds, Bridgeport Hospital | Advisor | 2019 |
Yale School of Medicine Internal Medicine Residency Program | Interviewer | 2019 |
American Society of Hematology | Reviewer | 2019 |
Acute Myeloid Leukemia/Myelodysplastic Syndromes Session, Korean Society of Hematology International Conference & 60th Annual Meeting | Chair | 2019 |
Annual Hematology Section Staff Appreciation Party, Yale Cancer Center | Host | 2019 |
Advanced Science Workshop on Myeloid Malignancies | Chair | 2019 |
4th Annual Hematologic Malignancies Symposium | Co-Chair | 2019 |
Saint Francis and Yale 4th Annual Hematologic Malignancies Symposium | Co-Chair | 2019 |
Oral Session, Korean Society of Hematology International Conference & 60th Annual Meeting | Chairperson | 2019 |
Oral Session, Korean Society of Hematology International Conference & 60th Annual Meeting | Chairperson | 2019 |
Annual Hematology Section Staff Appreciation Party | Host | 2019 - Present |
Developmental Therapeutics Research Program, Yale University | Member | 2019 - Present |
Cancer Outcomes, Public Policy, and Effectiveness Research Center (COPPER) | Member | 2019 - Present |
Developmental Therapeutics Research Program, Yale University | Member | 2019 - Present |
Cancer Outcomes, Public Policy, and Effectiveness Research Center (COPPER), Yale University | Member | 2019 - Present |
Integrating Genomics into Risk Stratification and Therapeutic Decisions, 60th American Society of Hematology Annual Meeting | Abstract Reviewer | 2018 |
American Society of Hematology | Integrating Genomics into Risk Stratification and Therapeutic Decisions | 2018 |
American Society of Hematology | Highlights of ASH in USA and Asia on myelodysplastic syndromes | 2018 |
Integrating Genomics into Risk Stratification and Therapeutic Decisions, 60th American Society of Hematology Annual Meeting | Moderator | 2018 |
Data Safety Review Board, Smilow Cancer Center | Vice Chair | 2018 - Present |
Haematology Journal | Ad-hoc reviewer | 2018 - Present |
Cancer Journal | Ad-hoc reviewer | 2018 - Present |
PLOS ONE Journal | Ad-hoc reviewer | 2018 - Present |
Clinical Leukemia, Lymphoma, and Myeloma Journal | Ad-hoc reviewer | 2018 - Present |
Bone Marrow Transplantation Journal | Ad-hoc reviewer | 2018 - Present |
Leukemia and Lymphoma Journal | Ad-hoc reviewer | 2018 - Present |
Leukemia Research Journal | Ad-hoc reviewer | 2018 - Present |
Expert Review of Hematology Journal | Ad-hoc reviewer | 2018 - Present |
Hematology/Oncology and Stem Cell Therapy Journal | Ad-hoc reviewer | 2018 - Present |
Clinical Epigenetics Journal | Ad-hoc reviewer | 2018 - Present |
Journal of the Royal Medical Services | Ad-hoc reviewer | 2018 - Present |
Blood Reviews | Editorial Board Member | 2018 - Present |
Leukemia and Lymphoma | Editorial Board Member | 2018 - Present |
Hemato Journal | Editorial Board Member | 2018 - Present |
Mortality Review Committee, Smilow Cancer Center | Member | 2017 - 2018 |
Novel Therapies for Elderly Patients with AML, 59th American Society of Hematology Annual Meeting | Abstract Reviewer | 2017 |
American Society of Hematology | Novel Therapies for Elderly Patients with AML | 2017 |
Novel Therapies for Elderly Patients with AML, 59th American Society of Hematology Annual Meeting | Moderator | 2017 |
Yale Hematology Research Seminar Series | Director | 2017 - Present |
New England Journal of Medicine | Ad-hoc reviewer | 2017 - Present |
Journal of Clinical Oncology | Ad-hoc reviewer | 2017 - Present |
Blood Journal | Ad-hoc reviewer | 2017 - Present |
Lancet Oncology Journal | Ad-hoc reviewer | 2017 - Present |
Leukemia Journal | Ad-hoc reviewer | 2017 - Present |
JAMA Oncology Journal | Ad-hoc reviewer | 2017 - Present |
Lancet Oncology Journal | Ad-hoc reviewer | 2017 - Present |
Yale School of Medicine Internal Medicine Residency Program | Interviewer | 2016 - Present |
Yale School of Medicine Hematology/Oncology Fellowship Program | Interviewer | 2016 - Present |
National Comprehensive Cancer Center Network | Participant | 2015 - 2018 |
The Swiss Cancer League | Ad-hoc reviewer | 2015 |
The Medical Research Council (MRC) of UK | Ad-hoc reviewer | 2015 |
Yale Affiliated Hospital Program | Lecturer | 2015 - Present |
American College of Physicians | Member | 2013 - 2014 |
Edward P. Evans Foundation, MDS Clinical Research Consortium, Aplastic Anemia & MDS International Foundation | Fellow | 2012 - 2014 |
American Society of Blood and Marrow Transplantation | Member | 2012 - 2013 |
American Society of Clinical Oncology | Member | 2011 - Present |
Transfusion Committee, Rochester General Hospital | Representative | 2009 |
American Society of Hematology | Member | 2008 - Present |
Medical Education Committee, Rochester General Hospital | Representative | 2007 - 2010 |
Graduate Medical Education Committee, Rochester General Hospital | Representative | 2006 - 2010 |
Clinical Investigation Committee, Rochester General Hospital | Representative | 2006 |
Cancer Patients Support groups, King Hussein Cancer Center, Jordan | Representative | 2003 - 2004 |
General Health Committee, Faculty of Engineering Technology, Amman, Jordan. | Director | 2003 |
Blood Donation Campaign, Faculty of Engineering Technology, Amman, Jordan | Coordinator | 2003 |
New Classifications of MDS/CMML, and Response Criteria, The 17th International Congress on Myelodysplastic Syndromes | Chair | 2003 |
Jordan Medical Association | Member | 2001 - Present |
Culture and Sports Committee, University of Jordan, Amman, Jordan | Representative | 2000 - 2001 |